0001564590-23-002737 | 10-K | XBRL Viewer | Acadia Healthcare Company INC

Print Document View Excel Document

Financial Information Combined Wholly-Owned Subsidiaries - Additional Information (Detail)	Dec. 31, 2022	Dec. 31, 2021	Oct. 14, 2020	Jun. 24, 2020
5.500% Senior Notes due 2028 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
5.000% Senior Notes due 2029 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%

Other Intangible Assets

12 Months Ended

Dec. 31, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

7. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2022 and 2021 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2022		December 31, 2021		December 31, 2022			December 31, 2021
Intangible assets subject to amortization:
Non-compete agreements	$	1,131	$	1,131	$	(1,131	)	$	(1,131	)

Intangible assets not subject to amortization:
Licenses and accreditations		11,512		11,600		—			—
Trade names		45,935		40,435		—			—
Certificates of need		18,594		18,110		—			—
		76,041		70,145		—			—
Total	$	77,172	$	71,276	$	(1,131	)	$	(1,131	)

All the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

During the second quarter of 2021, the Company sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, the Company sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition. These dispositions are reflected in other investing activities in the consolidated statement of cash flows.

Equity-Based Compensation

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

16. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At December 31, 2022, a maximum of 12,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 3,133,811 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $29.6 million, $37.5 million and $22.5 million in equity-based compensation expense for the years ended December 31, 2022, 2021 and 2020, respectively. Stock compensation expense for the years ended December 31, 2022, 2021 and 2020 is impacted by forfeiture adjustments and restricted stock unit adjustments based on actual performance compared to vesting targets. At December 31, 2022, there was $61.9 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.4 years.

At December 31, 2022, there were no warrants outstanding. The Company recognized a deferred income tax benefit of $8.0 million, $9.6 million and $5.5 million for the years ended December 31, 2022, 2021 and 2020, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2020, 2021 and 2022 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2020		1,360,068		$	39.40
Options granted		507,600			33.13
Options exercised		(68,700	)		29.15
Options cancelled		(288,662	)		39.67
Options outstanding at December 31, 2020		1,510,306			37.56
Options granted		324,320			57.53
Options exercised		(558,322	)		39.45
Options cancelled		(170,235	)		40.08
Options outstanding at December 31, 2021		1,106,069			42.07
Options granted		334,260			55.73
Options exercised		(285,577	)		40.66
Options cancelled		(175,475	)		46.98
Options outstanding at December 31, 2022		979,277		$	46.27		7.44	$	35,303
Options exercisable at December 31, 2022		301,827		$	41.43		5.69	$	12,341

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2022, 2021 and 2020:

	Year Ended December 31,
	2022			2021			2020
Weighted average grant-date fair value of options	$	20.72		$	20.64		$	12.37
Risk-free interest rate		2.0	%		0.9	%		1.6	%
Expected volatility		39	%		40	%		41	%
Expected life (in years)		5.0			5.0			5.0

The Company’s estimate of expected volatility for stock options is based upon the volatility of its stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U. S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2020, 2021 and 2022 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2020		805,136		$	34.14
Granted		637,312			25.82
Cancelled		(129,683	)		34.56
Vested		(289,769	)		35.88
Unvested at December 31, 2020		1,022,996		$	28.41
Granted		352,430			58.32
Cancelled		(82,751	)		39.63
Vested		(366,048	)		30.81
Unvested at December 31, 2021		926,627		$	37.84
Granted		650,396			64.65
Cancelled		(145,205	)		49.03
Vested		(386,616	)		32.64
Unvested at December 31, 2022		1,045,202		$	54.89

Restricted stock unit activity during 2020, 2021 and 2022 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2020		447,357		$	38.89
Granted		583,680			10.60
Performance adjustment		117,772			13.50
Cancelled		(63,056	)		43.35
Vested		(12,691	)		42.09
Unvested at December 31, 2020		1,073,062		$	20.15
Granted		149,416			61.52
Performance adjustment		465,993			25.49
Cancelled		—			—
Vested		(184,051	)		42.30
Unvested at December 31, 2021		1,504,420		$	23.20
Granted		105,311			73.96
Performance adjustment		182,543			33.05
Cancelled		—			—
Vested		(518,474	)		43.16
Unvested at December 31, 2022		1,273,800		$	20.69

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions.

Property and Equipment

12 Months Ended

Dec. 31, 2022

Property Plant And Equipment [Abstract]

Property and Equipment

6. Property and Equipment

Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):

	December 31,
	2022			2021
Land	$	169,137		$	154,376
Building and improvements		1,797,809			1,683,560
Equipment		292,200			253,100
Construction in progress		349,473			221,249
		2,608,619			2,312,285
Less: accumulated depreciation		(656,574	)		(541,126	)
Property and equipment, net	$	1,952,045		$	1,771,159

During the year ended December 31, 2021, the Company recorded non-cash impairment charges of $24.3 million related primarily to the closure of certain facilities. During the second quarter of 2021, the Company opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter 2021, the Company recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

The Company has recorded assets held for sale within other current assets on the consolidated balance sheets for closed properties actively marketed of $8.3 million and $15.8 million at December 31, 2022 and 2021, respectively.

Long-Term Debt (Debt Issuance Costs) - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt issuance costs	$ 12.6	$ 14.8
Accumulated amortization	4.6	2.4
Amortization expenses reported as interest expense	$ 2.2	$ 2.8	$ 9.8

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan [Member] \| 401(k) [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution expense	$ 6.6	$ 2.8	$ 3.8

Variable Interest Entities - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Facility	Dec. 31, 2021 USD ($)
Variable Interest Entity [Line Items]
Consolidated assets	$ 4,987,901	$ 4,768,078
Consolidated liabilities	$ 2,086,917	2,185,201
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of facilities operated through non-wholly owned subsidiaries \| Facility	8
Consolidated assets	$ 434,173	320,639
Consolidated liabilities	$ 24,361	$ 24,110
Variable Interest Entity, Primary Beneficiary [Member] \| Minimum [Member]
Variable Interest Entity [Line Items]
Variable interest entity, ownership percentage	65.00%
Variable Interest Entity, Primary Beneficiary [Member] \| Maximum [Member]
Variable Interest Entity [Line Items]
Variable interest entity, ownership percentage	86.00%

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary providing coverage for up to $10.0 million per claim through August 31, 2022 and $5.0 million and $10.0 million for certain other claims thereafter. The Company has obtained reinsurance coverage from a third party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $75.0 million or $70.0 million for certain other claims in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. The reserve for professional and general liability risks was estimated based on historical claims, prior settlements and judgments, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The Company recorded an unfavorable adjustment of $5.9 million to its estimated liability for self-insured professional and general liability claims during the year ended December 31, 2022, relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017 to 2018 period. The professional and general liability reserve was $103.6 million at December 31, 2022, of which $12.1 million was included in other accrued liabilities and $91.5 million was included in other long-term liabilities. The professional and general liability reserve was $87.8 million at

December 31, 2021, of which $11.9 million was included in other accrued liabilities and $75.9 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $37.8 million at December 31, 2022, of which $10.2 million was included in other current assets and $27.6 million was included in other assets, and such receivable was $37.9 million at December 31, 2021, of which $10.8 million was included in other current assets and $27.1 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $24.2 million at December 31, 2022, of which $12.0 million was included in accrued salaries and benefits and $12.2 million was included in other long-term liabilities, and such liability was $23.6 million at December 31, 2021, of which $12.0 million was included in accrued salaries and benefits and $11.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $117.8 million, $106.7 million and $95.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful life, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows. During the second quarter of 2021, the Company opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, the Company recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

The Company performed an impairment review of long-lived assets in the fourth quarter of 2022 and 2021 and recorded no impairment. The impairment review of long-lived assets in the fourth quarter of 2020 indicated the carrying amounts of certain of the Company’s long-lived assets may not be recoverable. This created a non-cash impairment of $4.2 million for the year ended December 31, 2020, which was recorded in loss on impairment on the Company’s consolidated statements of operations.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate the carrying value of a reporting unit may not be recoverable.

As of the Company’s annual impairment tests on October 1, 2022 and October 1, 2021, the Company had one reporting unit, behavioral health services. The fair value of the Company’s behavioral health services reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded.

As of the Company’s annual impairment test on October 1, 2020, the Company had two operating segments for segment reporting purposes, U.S. facilities and U.K. facilities, each of which represented a reporting unit for purposes of the Company’s goodwill impairment test.

The Company’s annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2020 considered recent financial performance, including the impacts of COVID-19 on certain portions of the U.K. business. The 2020 impairment test of the U.K. facilities indicated carrying value of the reporting unit exceeded the estimated fair value and resulted in a non-cash loss on impairment of the remaining goodwill of the U.K. facilities of $356.2 million. The non-cash loss on impairment is included in loss on sale within discontinued operations in the consolidated statements of operations. As of the Company’s impairment test on October 1, 2020, the fair value of the U.S. facilities reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded. Additionally, for the year ended December 31, 2020, the Company recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statements of operations.

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2022		2021
Prepaid expenses	$	27,052	$	22,292
Other receivables		15,371		10,786
Workers’ compensation deposits – current portion		12,000		12,000
Insurance receivable – current portion		10,158		10,807
Assets held for sale		8,347		15,808
Income taxes receivable		5,767		1,523
Inventory		5,087		4,786
Other		2,255		1,884
Other current assets	$	86,037	$	79,886

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2022		2021
Accrued expenses	$	26,699	$	26,791
Accrued interest		17,596		17,418
Cost report payable		13,738		6,487
Insurance liability – current portion		12,128		11,923
Accrued property taxes		9,009		8,375
Government relief funds		8,975		8,550
Contract liabilities		6,653		30,371
Income taxes payable		1,338		5,540
Finance lease liabilities		990		990
Other		13,466		10,054
Other accrued liabilities	$	110,592	$	126,499

Stock Compensation

The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation .” The Company uses the Black-Scholes valuation model to determine grant-date fair value for stock options and recognizes straight-line amortization of share-based compensation expense over the requisite service period of the respective awards. The fair values of restricted stock units are determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at their Monte-Carlo simulation value for units subject to market conditions.

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options and non-vested shares, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred

taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

The Company established accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. The Company accrues for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Management believes that the positions taken on previously filed tax returns are reasonable and has not established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by the Company resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect the Company’s potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.

Recent Accounting Pronouncements

In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832)” (“ASU 2021-10”). ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. ASU 2021-10 applies to all business entities except for not-for-profit entities within the scope of Topic 958, Not-for-Profit Entities, and employee benefit plans within the scope of Topic 960, Plan Accounting— Defined Benefit Pension Plans, Topic 962, Plan Accounting—Defined Contribution Pension Plans, and Topic 965, Plan Accounting—Health and Welfare Benefit Plans that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance (for example, a grant model within IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or Subtopic 958-605, Not-For-Profit Entities—Revenue Recognition). ASU 2021-10 is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company adopted the ASU for the year ended December 31, 2022. See Note 10 – The CARES Act for additional information on the Company’s accounting for government grants received.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2024. Entities may adopt ASU 2020-04 as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. There is no significant impact on the Company’s consolidated financial statements.

Property and Equipment - Additional information (Detail) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($) Bed	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)
Property Plant And Equipment [Line Items]
Loss on impairment	$ 1.1	$ 23.2	$ 24.3
Number of beds, replacement facility \| Bed		260
Other Assets [Member]
Property Plant And Equipment [Line Items]
Assets held for sale			$ 15.8	$ 8.3

Noncontrolling Interests - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	8
Non-Wholly Owned Subsidiaries [Member] \| Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	65.00%
Non-Wholly Owned Subsidiaries [Member] \| Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	86.00%

Long-Term Debt (Redemption of 6.125% Senior Notes and 5.125% Senior Notes) - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Jun. 10, 2020	Dec. 31, 2022	Dec. 31, 2020	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		6.125%			6.125%
Term loan remaining balance due date		Jun. 24, 2020
Debt instrument, redemption price percentage of principal amount	100.00%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		5.125%		5.125%
Term loan remaining balance due date		Jun. 24, 2020
Debt instrument, redemption price percentage of principal amount	100.00%
6.125% Senior Notes Due 2021 and 5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt extinguishment charge			$ 3.3

Earnings Per Share

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Earnings Per Share

4. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2022, 2021 and 2020 (in thousands, except per share amounts):

	Year Ended December 31,
	2022		2021			2020
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	273,139	$	203,276		$	140,258
Loss from discontinued operations		—		(12,641	)		(812,390	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	273,139	$	190,635		$	(672,132	)
Denominator:
Weighted average shares outstanding for basic earnings per share		89,680		88,769			87,875
Effects of dilutive instruments		1,875		2,024			720
Shares used in computing diluted earnings per common share		91,555		90,793			88,595

Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	3.05	$	2.29		$	1.60
Loss from discontinued operations		—		(0.14	)		(9.25	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	3.05	$	2.15		$	(7.65	)

Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	2.98	$	2.24		$	1.58
Loss from discontinued operations		—		(0.14	)		(9.17	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	2.98	$	2.10		$	(7.59	)

Approximately 0.1 million, 0.3 million and 1.9 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2022, 2021 and 2020, respectively, because their effect would have been anti-dilutive.

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 273,139	$ 203,276	$ 140,258
Loss from discontinued operations		(12,641)	(812,390)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 273,139	$ 190,635	$ (672,132)
Denominator:
Weighted average shares outstanding for basic earnings per share	89,680	88,769	87,875
Effects of dilutive instruments	1,875	2,024	720
Shares used in computing diluted earnings per common share	91,555	90,793	88,595
Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 3.05	$ 2.29	$ 1.60
Loss from discontinued operations		(0.14)	(9.25)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	3.05	2.15	(7.65)
Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	2.98	2.24	1.58
Loss from discontinued operations		(0.14)	(9.17)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 2.98	$ 2.10	$ (7.59)

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

17. Income Taxes

Provision for income taxes from continuing operations consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2022		2021			2020
Current:
Federal	$	63,041	$	48,292		$	(18,215	)
State		13,769		6,715			4,981
Foreign		755		778			732
Total current		77,565		55,785			(12,502	)
Deferred:
Federal		9,808		13,339			46,442
State		6,377		(1,892	)		564
Foreign		360		325			6,102
Total deferred provision		16,545		11,772			53,108
Provision for income taxes	$	94,110	$	67,557		$	40,606

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2022			2021			2020
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		21.0	%
Impact of foreign operations		(0.1	)		1.7			(0.5	)
Effects of statutory rate change		—			—			3.2
State income taxes, net of federal tax effect		4.7			3.9			5.1
Permanent differences		0.1			1.7			1.5
Change in valuation allowance		0.2			(2.8	)		127.4
Unrecognized tax benefit release		—			(0.9	)		(0.4	)
Federal tax credits		(0.6	)		(0.8	)		(1.0	)
Basis recognition related to foreign divestiture		—			—			(129.9	)
CARES Act impacts to net operating losses		—			—			(4.5	)
Other		(0.1	)		0.7			0.2
Effective income tax rate		25.2	%		24.5	%		22.1	%

For the year ended December 31, 2022, the provision for income taxes was $94.1 million, reflecting an effective tax rate of 25.2%, compared to $67.6 million, reflecting an effective tax rate of 24.5%, for the year ended December 31, 2021.

The domestic and foreign components of income from continuing operations before income taxes for continuing operations are as follows (in thousands):

	Year Ended December 31,
	2022		2021		2020
Foreign	$	5,420	$	5,596	$	9,904
Domestic		368,723		270,164		173,893
Income from continuing operations before income taxes	$	374,143	$	275,760	$	183,797

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2022 and December 31, 2021 were as follows (in thousands):

	December 31,
	2022			2021
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	7,333		$	9,354
Capital loss carryovers		215,745			215,367
Bad debt allowance		1,148			1,083
Accrued compensation and severance		18,784			18,241
Insurance reserves		20,924			18,847
Leases		862			896
Accrued expenses		—			5,768
Interest carryforwards		2,639			3,396
Lease right-of-use liabilities		26,277			26,154
Fixed asset basis difference		2,128			—
Other assets		8,987			8,066
Total gross deferred tax assets		304,827			307,172
Less: valuation allowance		(217,705	)		(217,325	)
Deferred tax assets		87,122			89,847
Deferred tax liabilities:
Fixed asset basis difference		—			(2,456	)
Prepaid items		(3,714	)		(2,882	)
Accrued expenses		(5,713	)		—
Intangible assets		(139,843	)		(126,446	)
Lease right-of-use assets		(24,960	)		(24,660	)
Investment in foreign subsidiary		(2,530	)		(4,691	)
Total deferred tax liabilities		(176,760	)		(161,135	)
Total net deferred tax liability	$	(89,638	)	$	(71,288	)

The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. At December 31, 2022 and 2021, the Company carried a valuation allowance against deferred tax assets of $217.7 million and $217.3 million, respectively. These amounts are primarily related to deferred tax assets related to the Company’s capital loss carryforward resulting from the U.K. Sale and certain state net operating losses. If the capital loss carryforward is not utilized, it will begin to expire in 2026.

As of December 31, 2022 and 2021, the Company had no federal net operating loss carryforwards. The foreign net operating loss carryforwards at December 31, 2022 and 2021 are approximately $0.1 million and $0.1 million, respectively, and have no expiration.

The Company has state net operating loss carryforwards at December 31, 2022 and 2021 of approximately $191.5 million and $227.3 million, respectively. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 2023 to 2036. In addition, the Company has certain state tax credits of $0.2 million which will begin to expire in 2030 if not utilized.

Income taxes receivable was $28.9 million and $24.6 million at December 31, 2022 and 2021, respectively. At December 31, 2022 and 2021, $23.1 million of income taxes receivable has been included in other assets due to anticipated delays in receipt of income tax refunds associated with amended tax return filings. The remaining $5.8 million and $1.5 million of income taxes receivable is included in other current assets in the December 31, 2022 and 2021 consolidated balance sheet, respectively. Income taxes payable of $1.3 million and $5.5 million at December 31, 2022 and 2021, respectively, was included in other accrued liabilities in the consolidated balance sheets.

The Company did not record any amounts related to unrecognized tax benefits at December 31, 2022 or 2021. The Company’s accounting policy is to record any interest and penalties as a component of income tax expense, when applicable. A reconciliation of the beginning and ending amount of unrecognized income tax benefits, exclusive of any interest and penalties, net of the federal benefit, is as follows (in thousands):

	2021
Balance at January 1	$	2,060
Additions based on tax positions related to the current year		—
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(2,060	)
Balance at December 31	$	—

The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar years 2019 through 2021. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. While no foreign jurisdictions are presently under examination, the Company may be subject to examination for calendar years 2018 through 2021. Generally, for state tax purposes, the Company’s 2017 through 2021 tax years remain open for examination by the tax authorities. At the date of this report, there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Credit Facilities and Contingent Consideration Liabilities

The carrying amounts and fair values of the Company’s New Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes at December 31, 2022 and 2021 were as follows (in thousands):

	Carrying Amount				Fair Value
	December 31,				December 31,
	2022		2021		2022		2021
New Credit Facility	$	471,489	$	584,418	$	471,489	$	584,418
5.500% Senior Notes due 2028	$	444,694	$	443,894	$	422,459	$	466,577
5.000% Senior Notes due 2029	$	469,609	$	468,907	$	433,214	$	481,802

Noncontrolling Interests

12 Months Ended

Dec. 31, 2022

Noncontrolling Interest [Abstract]

Noncontrolling Interests

12. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At December 31, 2022, the Company operated eight facilities through non-wholly owned subsidiaries. The Company owns between approximately 65% and 86% of the equity interests of these entities and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions. The Company consolidates the operations of each facility based on its status as primary beneficiary, as further discussed in Note 13 – Variable Interest Entities. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2021	$	55,315
Contributions from noncontrolling partners in joint ventures		6,734
Net income attributable to noncontrolling interests		4,927
Distributions to noncontrolling partners in joint ventures		(1,588	)
Balance at December 31, 2021		65,388
Contributions from noncontrolling partners in joint ventures		21,162
Net income attributable to noncontrolling interests		6,894
Acquisition of ownership interests from noncontrolling partners		(4,183	)
Distributions to noncontrolling partners in joint ventures		(1,004	)
Balance at December 31, 2022	$	88,257

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 280,033	$ 195,562	$ (669,199)
Other comprehensive income (loss):
Foreign currency translation (loss) gain		(4,260)	61,247
Gain (loss) on derivative instruments, net of tax of $0.0 million, $0.1 million and $(3.9) million, respectively		19	(11,272)
Pension liability adjustment, net of tax of $0.0 million, $0.0 million and $(0.8) million, respectively			(6,456)
U.K. Sale		375,606
Other comprehensive income		371,365	43,519
Comprehensive income (loss)	280,033	566,927	(625,680)
Comprehensive income attributable to noncontrolling interests	(6,894)	(4,927)	(2,933)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ 273,139	$ 562,000	$ (628,613)

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Nov. 13, 2020
Debt Instrument [Line Items]
Less: unamortized debt issuance costs, discount and premium	$ (12,647)	$ (14,811)
Long-term debt	1,385,791	1,497,220
Less: current portion	(21,250)	(18,594)
Long-term debt	1,364,541	1,478,626
Term Loan A Facility [Member]
Debt Instrument [Line Items]
Revolving Facility			$ 352,400
Credit Facility [Member] \| Term Loan A Facility [Member]
Debt Instrument [Line Items]
Revolving Facility	398,438	417,031
Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Revolving Facility	75,000	170,000
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Senior Notes	450,000	450,000
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 475,000	$ 475,000

The CARES Act - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Apr. 24, 2020	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
CARES Act [Line Items]
Income from relief fund			$ 21,451	$ 17,900	$ 32,819
Expected repay of payroll tax deferrals		$ 39,300
CARES Act [Member]
CARES Act [Line Items]
Offer of eligible relief amount			100,000,000
Additional offer of eligible relief amount	$ 75,000,000
Cash benefit relating to delay of payment of social security payroll taxes			$ 39,300
CARES Act [Member] \| Medicare [Member]
CARES Act [Line Items]
Percentage of increase in medicare reimbursement rate					2.00%
Repayment of advanced payments				25,100
Percentage of reduced in medicare reimbursement rate			1.00%
CARES Act [Member] \| Public Health and Social Services Emergency Fund [Member]
CARES Act [Line Items]
Receipt of CARES Act of 2020 aid amount					$ 34,900
Income from relief fund			$ 21,500	17,900
Receipt of additional CARES Act of 2020 aid amount			7,700	$ 24,200
CARES Act [Member] \| Public Health and Social Services Emergency Fund [Member] \| American Rescue Plan
CARES Act [Line Items]
Receipt of additional CARES Act of 2020 aid amount			14,200
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member]
CARES Act [Line Items]
Amount of advance payment received					$ 45,200
Repayments of medicare advance payments			$ 20,100

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating losses and tax credit carryforwards - federal and state	$ 7,333	$ 9,354
Capital loss carryovers	215,745	215,367
Bad debt allowance	1,148	1,083
Accrued compensation and severance	18,784	18,241
Insurance reserves	20,924	18,847
Leases	862	896
Accrued expenses		5,768
Interest carryforwards	2,639	3,396
Lease right-of-use liabilities	26,277	26,154
Fixed asset basis difference	2,128
Other assets	8,987	8,066
Total gross deferred tax assets	304,827	307,172
Less: valuation allowance	(217,705)	(217,325)
Deferred tax assets	87,122	89,847
Deferred tax liabilities:
Fixed asset basis difference		(2,456)
Prepaid items	(3,714)	(2,882)
Accrued expenses	(5,713)
Intangible assets	(139,843)	(126,446)
Lease right-of-use assets	(24,960)	(24,660)
Investment in foreign subsidiary	(2,530)	(4,691)
Total deferred tax liabilities	(176,760)	(161,135)
Total net deferred tax liability	$ (89,638)	$ (71,288)

Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Accumulated Other Comprehensive Loss

14. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2020	$	(434,633	)	$	24,958		$	(5,209	)	$	(414,884	)
Foreign currency translation gain (loss)		61,532			—			(285	)		61,247
Loss on derivative instruments, net of tax of $(3.9) million		—			(11,272	)		—			(11,272	)
Pension liability adjustment, net of tax of $(0.8) million		—			—			(6,456	)		(6,456	)
Balance at December 31, 2020		(373,101	)		13,686			(11,950	)		(371,365	)
Foreign currency translation gain (loss)		(4,293	)		—			33			(4,260	)
Gain on derivative instruments, net of tax of $0.1 million		—			19			—			19
U.K. Sale		377,394			(13,705	)		11,917			375,606
Balance at December 31, 2021	$	—		$	—		$	—		$	—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Components of Provision for Income Taxes

Provision for income taxes from continuing operations consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2022		2021			2020
Current:
Federal	$	63,041	$	48,292		$	(18,215	)
State		13,769		6,715			4,981
Foreign		755		778			732
Total current		77,565		55,785			(12,502	)
Deferred:
Federal		9,808		13,339			46,442
State		6,377		(1,892	)		564
Foreign		360		325			6,102
Total deferred provision		16,545		11,772			53,108
Provision for income taxes	$	94,110	$	67,557		$	40,606

Effective Income Tax Rate

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2022			2021			2020
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		21.0	%
Impact of foreign operations		(0.1	)		1.7			(0.5	)
Effects of statutory rate change		—			—			3.2
State income taxes, net of federal tax effect		4.7			3.9			5.1
Permanent differences		0.1			1.7			1.5
Change in valuation allowance		0.2			(2.8	)		127.4
Unrecognized tax benefit release		—			(0.9	)		(0.4	)
Federal tax credits		(0.6	)		(0.8	)		(1.0	)
Basis recognition related to foreign divestiture		—			—			(129.9	)
CARES Act impacts to net operating losses		—			—			(4.5	)
Other		(0.1	)		0.7			0.2
Effective income tax rate		25.2	%		24.5	%		22.1	%

Summary of Domestic and Foreign Components of Income from Continuing Operations before Income Taxes

The domestic and foreign components of income from continuing operations before income taxes for continuing operations are as follows (in thousands):

	Year Ended December 31,
	2022		2021		2020
Foreign	$	5,420	$	5,596	$	9,904
Domestic		368,723		270,164		173,893
Income from continuing operations before income taxes	$	374,143	$	275,760	$	183,797

Deferred Tax Assets and Liabilities

	December 31,
	2022			2021
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	7,333		$	9,354
Capital loss carryovers		215,745			215,367
Bad debt allowance		1,148			1,083
Accrued compensation and severance		18,784			18,241
Insurance reserves		20,924			18,847
Leases		862			896
Accrued expenses		—			5,768
Interest carryforwards		2,639			3,396
Lease right-of-use liabilities		26,277			26,154
Fixed asset basis difference		2,128			—
Other assets		8,987			8,066
Total gross deferred tax assets		304,827			307,172
Less: valuation allowance		(217,705	)		(217,325	)
Deferred tax assets		87,122			89,847
Deferred tax liabilities:
Fixed asset basis difference		—			(2,456	)
Prepaid items		(3,714	)		(2,882	)
Accrued expenses		(5,713	)		—
Intangible assets		(139,843	)		(126,446	)
Lease right-of-use assets		(24,960	)		(24,660	)
Investment in foreign subsidiary		(2,530	)		(4,691	)
Total deferred tax liabilities		(176,760	)		(161,135	)
Total net deferred tax liability	$	(89,638	)	$	(71,288	)

Unrecognized Income Tax Benefits Net of Federal Benefit

A reconciliation of the beginning and ending amount of unrecognized income tax benefits, exclusive of any interest and penalties, net of the federal benefit, is as follows (in thousands):

	2021
Balance at January 1	$	2,060
Additions based on tax positions related to the current year		—
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(2,060	)
Balance at December 31	$	—

Leases - Schedule of Leases on Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Finance lease right-of-use assets	$ 8,250	$ 8,627
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net
Operating lease right-of-use assets	$ 135,238	$ 133,761
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Operating lease right-of-use assets	Operating lease right-of-use assets
Total	$ 143,488	$ 142,388
Finance lease liabilities	$ 990	$ 990
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other accrued liabilities	Other accrued liabilities
Operating lease liabilities	$ 26,463	$ 23,348
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Operating lease liabilities	Operating lease liabilities
Finance lease liabilities	$ 10,858	$ 10,807
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Operating lease liabilities	$ 116,429	$ 116,841
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Operating lease liabilities	Operating lease liabilities
Total	$ 154,740	$ 151,986

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2022		2021
Prepaid expenses	$	27,052	$	22,292
Other receivables		15,371		10,786
Workers’ compensation deposits – current portion		12,000		12,000
Insurance receivable – current portion		10,158		10,807
Assets held for sale		8,347		15,808
Income taxes receivable		5,767		1,523
Inventory		5,087		4,786
Other		2,255		1,884
Other current assets	$	86,037	$	79,886

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2022		2021
Accrued expenses	$	26,699	$	26,791
Accrued interest		17,596		17,418
Cost report payable		13,738		6,487
Insurance liability – current portion		12,128		11,923
Accrued property taxes		9,009		8,375
Government relief funds		8,975		8,550
Contract liabilities		6,653		30,371
Income taxes payable		1,338		5,540
Finance lease liabilities		990		990
Other		13,466		10,054
Other accrued liabilities	$	110,592	$	126,499

Derivatives - Additional Information (Detail) - 1 months ended Aug. 31, 2019 - Cross Currency Swap Assets [Member]	USD ($)	GBP (£)	GBP (£)
Derivative [Line Items]
Notional amount	$ 650,000,000.0		£ 538,100,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 25,400,000

Financial Information Combined Wholly-Owned Subsidiaries - Summarized Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Financial Statements, Captions [Line Items]
Current assets	$ 506,125	$ 495,031
Property and equipment, net	1,952,045	1,771,159
Goodwill	2,222,805	2,199,937	$ 2,105,264
Current liabilities	388,326	404,861
Long-term debt	1,364,541	1,478,626
Redeemable noncontrolling interests	88,257	65,388	55,315
Total equity	2,812,727	2,517,489	$ 1,899,456	$ 2,505,381
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Current assets	396,553	349,250
Property and equipment, net	1,517,893	1,166,409
Goodwill	2,105,227	2,086,978
Total noncurrent assets	3,921,336	3,527,700
Current liabilities	345,606	340,514
Long-term debt	1,364,541	1,478,626
Total noncurrent liabilities	1,629,750	1,688,326
Total equity	$ 2,342,533	$ 1,848,110

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):

	December 31,
	2022			2021
Land	$	169,137		$	154,376
Building and improvements		1,797,809			1,683,560
Equipment		292,200			253,100
Construction in progress		349,473			221,249
		2,608,619			2,312,285
Less: accumulated depreciation		(656,574	)		(541,126	)
Property and equipment, net	$	1,952,045		$	1,771,159

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		12 Months Ended
	Mar. 12, 2013	Dec. 31, 2022
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000.0
Debt instrument interest rate	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year
Term loan remaining balance due date		Jun. 24, 2020

Income Taxes - Unrecognized Income Tax Benefits Net of Federal Benefit (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Income Tax Disclosure [Abstract]
Balance at January 1	$ 2,060
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities	(2,060)
Balance at December 31	$ 0

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Schedule of Leases on Consolidated Balance Sheet

The Company recorded the following at December 31, 2022 and 2021 on the consolidated balance sheets (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2022		December 31, 2021
Finance lease right-of-use assets	Property and equipment, net	$	8,250	$	8,627
Operating lease right-of-use assets	Operating lease right-of-use assets		135,238		133,761
Total		$	143,488	$	142,388

Lease Liabilities	Balance Sheet Classification	December 31, 2022		December 31, 2021
Current:
Finance lease liabilities	Other accrued liabilities	$	990	$	990
Operating lease liabilities	Current portion of operating lease liabilities		26,463		23,348
Noncurrent:
Finance lease liabilities	Other liabilities		10,858		10,807
Operating lease liabilities	Operating lease liabilities		116,429		116,841
Total		$	154,740	$	151,986

Schedule of Weighted-average Remaining Lease Terms and Discount Rates

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2022 and 2021:

	December 31,
	2022			2021
Weighted-average remaining lease term (in years):
Finance		21.9		22.9
Operating		8.4		9.1

Weighted-average discount rate:
Finance		5.1	%		5.1	%
Operating		5.0	%		5.1	%

Schedule of Lease Cost

The Company recorded the following lease costs for the years ended December 31, 2022, 2021 and 2020 (in thousands):

	Year Ended December 31,
	2022		2021		2020
Finance lease costs:
Depreciation of leased assets		378		378		868
Interest of lease liabilities		1,041		2,174		3,214
Total finance lease costs	$	1,419	$	2,552	$	4,082

Operating lease costs		34,349		28,233		27,050
Variable lease costs		3,129		2,488		2,501
Short term lease costs		2,605		3,257		3,558
Other lease costs		5,379		4,541		4,253
Total rents and leases	$	45,462	$	38,519	$	37,362

Total lease costs	$	46,881	$	41,071	$	41,444

Schedule of Undiscounted Cash Flows for Finance and Operating Leases

Undiscounted future cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2022 (in thousands):

	Finance Leases		Operating Leases
2023	$	990	$	32,818
2024		1,007		29,568
2025		1,089		25,146
2026		1,180		19,251
2027		1,089		12,380
Thereafter		21,821		62,653
Total minimum lease payments		27,176		181,816
Less: amount of lease payments representing interest		15,328		38,924
Present value of future minimum lease payments		11,848		142,892
Less: Current portion of lease liabilities		990		26,463
Noncurrent lease liabilities	$	10,858	$	116,429

Schedule of Supplemental Data

Supplemental data for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands):

	Year Ended December 31,
	2022			2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	33,836		$	27,508	$	26,810
Operating cash flows for finance leases	$	1,041		$	2,174	$	3,214
Financing cash flows for finance leases	$	(51	)	$	31,136	$	551

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	31,294		$	63,279	$	21,285
Finance leases	$	—		$	—	$	—

U.K. Sale

12 Months Ended

Dec. 31, 2022

Discontinued Operations And Disposal Groups [Abstract]

U.K. Sale

9. U.K. Sale

On January 19, 2021, the Company completed the U.K. Sale pursuant to a Share Purchase Agreement in which it sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of the Company’s U.K. operations. The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current British Pounds (“GBP”) to U.S. Dollars (“USD”) exchange rate, cash retained by the buyer and transaction costs. The Company used the net proceeds of approximately $1,425 million (excluding cash retained by the buyer) along with cash on the balance sheet to reduce debt by $1,640 million during the first quarter of 2021 as described in Note 11 – Long-Term Debt.

As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. In December 2020, the Company’s U.K. operations met the criteria to be classified as assets held for sale. The carrying value of the U.K. operations was written down to fair value less costs to sell in the consolidated balance sheet at December 31, 2020. This resulted in a loss on sale of $867.3 million, which includes approximately $356.2 million of non-cash goodwill impairment, recorded within discontinued operations in the consolidated statement of operations. During the first quarter of 2021, an additional $14.3 million was recorded as a loss on sale primarily resulting from an increase in the U.K. operations carrying value.

For the years ended December 31, 2021 and 2020, results of operations of the U.K. operations were as follows (in thousands):

	Year Ended December 31,
	2021			2020
Revenue	$	62,520		$	1,119,768
Salaries, wages and benefits		35,937			632,134
Professional fees		6,815			127,291
Supplies		2,217			38,285
Rents and leases		2,509			47,748
Other operating expenses		6,682			113,534
Depreciation and amortization		—			74,935
Interest expense, net		10			(417	)
Loss on sale		13,490			867,324
Loss on impairment		—			20,239
Transaction-related expenses		6,265			8,719
Total expenses		73,925			1,929,792
Loss from discontinued operations before income taxes		(11,405	)		(810,024	)
Provision for income taxes		1,236			2,366
Loss from discontinued operations	$	(12,641	)	$	(812,390	)

The consolidated cash flows for the year ended December 31, 2020 related to the discontinued U.K. operations includes cash paid for capital expenditures of $48.4 million.

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (the “U.S.”) and Puerto Rico. At December 31, 2022, the Company operated 250 behavioral healthcare facilities with approximately 11,000 beds in 39 states and Puerto Rico.

On January 19, 2021, the Company completed the sale of its operations in the United Kingdom (the “U.K.”) to RemedcoUK Limited, a company organized under the laws of England and Wales and owned by funds managed or advised by Waterland Private Equity Fund VII (the “U.K. Sale”). The U.K. Sale allowed the Company to reduce its indebtedness and focus on its U.S. operations. As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. See Note 9 – U.K. Sale.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $124.3 million, $108.2 million and $97.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Equity - Additional Information (Detail) - shares	12 Months Ended
Equity - Additional Information (Detail) - shares	Dec. 31, 2022	Dec. 31, 2021
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000	10,000,000
Common stock, number of shares proposed to be issued	180,000,000	180,000,000
Common stock voting rights	one vote for each share
Maximum [Member]
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000
Common stock, number of shares proposed to be issued	180,000,000

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

8. Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

The Company elected the accounting policy practical expedients by class of underlying asset in ASC 842 “Leases” to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as

right-of-use assets and liabilities on the consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

Operating lease liabilities are recorded at the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates were calculated based on information available at the lease commencement date. The Company reviews service agreements for embedded leases and records right-of-use assets and liabilities as necessary.

Lease Position

The Company recorded the following at December 31, 2022 and 2021 on the consolidated balance sheets (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2022		December 31, 2021
Finance lease right-of-use assets	Property and equipment, net	$	8,250	$	8,627
Operating lease right-of-use assets	Operating lease right-of-use assets		135,238		133,761
Total		$	143,488	$	142,388

Lease Liabilities	Balance Sheet Classification	December 31, 2022		December 31, 2021
Current:
Finance lease liabilities	Other accrued liabilities	$	990	$	990
Operating lease liabilities	Current portion of operating lease liabilities		26,463		23,348
Noncurrent:
Finance lease liabilities	Other liabilities		10,858		10,807
Operating lease liabilities	Operating lease liabilities		116,429		116,841
Total		$	154,740	$	151,986

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2022 and 2021:

	December 31,
	2022			2021
Weighted-average remaining lease term (in years):
Finance		21.9		22.9
Operating		8.4		9.1

Weighted-average discount rate:
Finance		5.1	%		5.1	%
Operating		5.0	%		5.1	%

Lease Costs

The Company recorded the following lease costs for the years ended December 31, 2022, 2021 and 2020 (in thousands):

	Year Ended December 31,
	2022		2021		2020
Finance lease costs:
Depreciation of leased assets		378		378		868
Interest of lease liabilities		1,041		2,174		3,214
Total finance lease costs	$	1,419	$	2,552	$	4,082

Operating lease costs		34,349		28,233		27,050
Variable lease costs		3,129		2,488		2,501
Short term lease costs		2,605		3,257		3,558
Other lease costs		5,379		4,541		4,253
Total rents and leases	$	45,462	$	38,519	$	37,362

Total lease costs	$	46,881	$	41,071	$	41,444

Other

Undiscounted future cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2022 (in thousands):

	Finance Leases		Operating Leases
2023	$	990	$	32,818
2024		1,007		29,568
2025		1,089		25,146
2026		1,180		19,251
2027		1,089		12,380
Thereafter		21,821		62,653
Total minimum lease payments		27,176		181,816
Less: amount of lease payments representing interest		15,328		38,924
Present value of future minimum lease payments		11,848		142,892
Less: Current portion of lease liabilities		990		26,463
Noncurrent lease liabilities	$	10,858	$	116,429

Supplemental data for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands):

	Year Ended December 31,
	2022			2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	33,836		$	27,508	$	26,810
Operating cash flows for finance leases	$	1,041		$	2,174	$	3,214
Financing cash flows for finance leases	$	(51	)	$	31,136	$	551

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	31,294		$	63,279	$	21,285
Finance leases	$	—		$	—	$	—

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Noncontrolling Interest [Abstract]
Beginning Balance	$ 65,388	$ 55,315
Contributions from noncontrolling partners in joint ventures	21,162	6,734
Net income attributable to noncontrolling interests	6,894	4,927
Acquisition of ownership interests from noncontrolling partners	(4,183)
Distributions to noncontrolling partners in joint ventures	(1,004)	(1,588)
Ending Balance	$ 88,257	$ 65,388

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	926,627	1,022,996	805,136
Granted, Number of Shares	650,396	352,430	637,312
Cancelled, Number of Shares	(145,205)	(82,751)	(129,683)
Vested, Number of Shares	(386,616)	(366,048)	(289,769)
Unvested, Number of Shares/Units, Ending balance	1,045,202	926,627	1,022,996
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 37.84	$ 28.41	$ 34.14
Granted, Weighted Average Grant-Date Fair Value	64.65	58.32	25.82
Cancelled, Weighted Average Grant-Date Fair Value	49.03	39.63	34.56
Vested, Weighted Average Grant-Date Fair Value	32.64	30.81	35.88
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 54.89	$ 37.84	$ 28.41

Acquisitions - Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 2,222,805	$ 2,199,937	$ 2,105,264
CenterPointe Behavioral Health System, LLC [Member]
Business Acquisition [Line Items]
Cash		5,640
Accounts receivable, net		9,358
Other current assets		1,981
Property and equipment		35,227
Goodwill		105,883
Intangible assets		825
Deferred tax assets		1,573
Operating lease right-of-use assets		29,245
Total assets acquired		189,732
Accounts payable		3,820
Accrued salaries and benefits		3,585
Current portion of operating lease liabilities		2,820
Other accrued liabilities		4,326
Deferred tax liability		1,805
Operating lease liabilities		27,850
Total liabilities assumed		44,206
Net assets acquired		$ 145,526

Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue From Contract With Customer [Abstract]

Schedule of Revenue Attributed to Each Category

The table below presents total revenue from continuing operations attributed to each category (in thousands):

	Year Ended December 31,
	2022		2021		2020
Acute inpatient psychiatric facilities	$	1,330,757	$	1,126,872	$	984,609
Specialty treatment facilities		564,671		510,929		452,805
Comprehensive treatment centers		419,940		385,635		349,217
Residential treatment centers		295,031		283,169		281,158
Other		—		7,789		22,140
Revenue	$	2,610,399	$	2,314,394	$	2,089,929

Schedule of Revenue and Percentage Generated by Each Payor Type in U.S Facilities

The following table presents revenue by payor type and as a percentage of revenue for continuing operations for the years ended December 31, 2022, 2021 and 2020 (in thousands):

	Year Ended December 31,
	2022					2021					2020
	Amount		%			Amount		%			Amount		%
Commercial	$	788,895		30.2	%	$	684,292		29.6	%	$	596,698		28.5	%
Medicare		394,227		15.1	%		364,598		15.8	%		330,070		15.8	%
Medicaid		1,319,600		50.6	%		1,147,884		49.6	%		1,037,852		49.7	%
Self-Pay		76,050		2.9	%		93,425		4.0	%		98,302		4.7	%
Other		31,627		1.2	%		24,195		1.0	%		27,007		1.3	%
Revenue	$	2,610,399		100.0	%	$	2,314,394		100.0	%	$	2,089,929		100.0	%

Summary of the Activity in Unearned Revenue in U.S. Facilities

A summary of the activity in contract liabilities is as follows (in thousands):

Balance at December 31, 2020	$	47,196
Payments received		11,739
Revenue recognized		(3,463	)
Medicare advance repayments		(25,101	)
Balance at December 31, 2021	$	30,371
Payments received		22,914
Revenue recognized		(26,497	)
Medicare advance repayments		(20,135	)
Balance at December 31, 2022	$	6,653

Income Taxes - Effective Income Tax Rate (Detail)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Detail)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. federal statutory rate on income before income taxes	21.00%	21.00%	21.00%
Impact of foreign operations	(0.10%)	1.70%	(0.50%)
Effects of statutory rate change			3.20%
State income taxes, net of federal tax effect	4.70%	3.90%	5.10%
Permanent differences	0.10%	1.70%	1.50%
Change in valuation allowance	0.20%	(2.80%)	127.40%
Unrecognized tax benefit release		(0.90%)	(0.40%)
Federal tax credits	(0.60%)	(0.80%)	(1.00%)
Basis recognition related to foreign divestiture			(129.90%)
CARES Act impacts to net operating losses			(4.50%)
Other	(0.10%)	0.70%	0.20%
Effective income tax rate	25.20%	24.50%	22.10%

Long-Term Debt (5.000% Senior Notes due 2029) - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Oct. 14, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt extinguishment costs			$ (24,650)	$ (7,233)
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Issued Senior Notes	$ 475,000
Debt instrument interest rate	5.00%	5.00%	5.00%
Debt instrument maturity date	Apr. 15, 2029
Interest on the notes		payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021
Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Debt extinguishment charge	$ 453,300
Debt extinguishment costs	$ 2,900

Income Taxes - Summary of Domestic and Foreign Components of Income from Continuing Operations before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
Income from continuing operations before income taxes	$ 374,143	$ 275,760	$ 183,797
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Income from continuing operations before income taxes	5,420	5,596	9,904
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Income from continuing operations before income taxes	$ 368,723	$ 270,164	$ 173,893

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Long-Term Debt (Redemption of 5.265% Senior Notes and 6.500% Senior Notes) - Additional Information (Detail) - USD ($) $ in Thousands				12 Months Ended
	Mar. 17, 2021	Mar. 01, 2021	Jan. 29, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt extinguishment costs				$ (24,650)	$ (7,233)
Redemption of 5.265% Senior Notes [Member]
Debt Instrument [Line Items]
Senior Notes			$ 650,000
Debt instrument interest rate			5.625%
Debt extinguishment costs	$ 3,300
Redemption of 6.500% Senior Notes [Member]
Debt Instrument [Line Items]
Senior Notes			$ 390,000
Debt instrument interest rate			6.50%
Debt extinguishment costs		$ 10,500
Cash paid for breakage costs		6,300
Write off of deferred financing costs		$ 4,200
Redemption of 5.265% Senior Notes and 6.500% Senior Notes [Member]
Debt Instrument [Line Items]
Term loan remaining balance due date			Jan. 29, 2021

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		12 Months Ended
	Feb. 16, 2016	Dec. 31, 2022
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000.0
Debt instrument interest rate	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016
Term loan remaining balance due date		Mar. 01, 2021

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2022

Business Combinations [Abstract]

Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed

The fair values of assets acquired and liabilities assumed in the CenterPointe acquisition were as follows (in thousands):

Cash	$	5,640
Accounts receivable, net		9,358
Other current assets		1,981
Property and equipment		35,227
Goodwill		105,883
Intangible assets		825
Deferred tax assets		1,573
Operating lease right-of-use assets		29,245
Total assets acquired		189,732
Accounts payable		3,820
Accrued salaries and benefits		3,585
Current portion of operating lease liabilities		2,820
Other accrued liabilities		4,326
Deferred tax liability		1,805
Operating lease liabilities		27,850
Total liabilities assumed		44,206
Net assets acquired	$	145,526

Summary of Changes in Goodwill

The following table summarizes changes in goodwill for the years ended December 31, 2022 and 2021 (in thousands):

Balance at January 1, 2021	$	2,105,264
Increase from acquisitions		97,122
2021 dispositions		(2,449	)
Balance at December 31, 2021		2,199,937
Increase from acquisitions		9,488
Adjustments related to 2021 acquisitions		8,761
Increase from contributions of redeemable noncontrolling interests		4,619
Balance at December 31, 2022	$	2,222,805

Transaction-related expenses represent costs primarily related to legal, accounting, termination, restructuring, management transition, acquisition and other similar costs. Transaction-related expenses comprised the following costs for the years ended December 31, 2022, 2021 and 2020 (in thousands):

	Year Ended December 31,
	2022		2021		2020
Management transition costs	$	11,575	$	—	$	—
Termination and restructuring costs		6,476		5,343		3,468
Legal, accounting and other acquisition-related costs		5,741		7,435		8,252
	$	23,792	$	12,778	$	11,720

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Leases - Schedule of Supplemental Data (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 33,836	$ 27,508	$ 26,810
Operating cash flows for finance leases	1,041	2,174	3,214
Financing cash flows for finance leases	(51)	31,136	551
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 31,294	$ 63,279	$ 21,285

U.K. Sale - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended			12 Months Ended
	Jan. 19, 2021	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of business		$ 1,500	$ 4,300			$ 1,511,020
Loss on sale				$ 14,300			$ 867,300
Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]				Debt extinguishment costs			Debt extinguishment costs
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of business	$ 1,525,000
Settlement of existing foreign currency hedging liabilities	85,000
Net proceeds from sale of business	$ 1,425,000
Cash from the balance sheet to reduce debt, amount				$ 1,640,000
Goodwill impairment loss					$ 356,200		$ 356,200
Cash paid for capital expenditures							$ 48,400

Employee Benefit Plans

12 Months Ended

Dec. 31, 2022

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

21. Employee Benefit Plans

The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company recorded expense of $6.6 million, $2.8 million and $3.8 million related to the 401(k) plan for the years ended December 31, 2022, 2021 and 2020, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Long-Term Debt (New Credit Facility) - Additional Information (Detail) - USD ($)		3 Months Ended		12 Months Ended
	Mar. 17, 2021	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 13, 2020
Debt Instrument [Line Items]
Date entered into a credit agreement	Mar. 17, 2021
Repayments of revolving facility				$ 95,000,000	$ 330,000,000	$ 100,000,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount							$ 352,400,000
New Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into a credit agreement	Mar. 17, 2021
Repayments of revolving facility			$ 60,000,000.0	$ 95,000,000.0
Proceeds from revolving facility		$ 70,000,000.0
Term loan remaining balance due date				Mar. 17, 2026
Maximum incremental debt amount				$ 480,000,000.0
Incremental debt amount maximum percentage of consolidated EBITDA				100.00%
Consolidated senior secured net leverage ratio				350.00%
Maximum consolidated net leverage ratio				500.00%
Minimum interest coverage ratio				300.00%
New Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				1.75%
New Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				0.75%
New Credit Facility [Member] \| March 31, 2023 to March 31, 2024 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				$ 5,300,000
New Credit Facility [Member] \| June 30, 2024 to March 31, 2025 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				8,000,000.0
New Credit Facility [Member] \| June 30, 2025 to December 31, 2025 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				10,600,000
New Credit Facility [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 425,000,000.0
Debt instrument maturity date	Mar. 17, 2026
New Credit Facility [Member] \| Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 20,000,000.0
New Credit Facility [Member] \| Swingline Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	20,000,000.0
New Credit Facility [Member] \| Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount				3,400,000
New Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 600,000,000.0		$ 160,000,000.0
Debt instrument maturity date	Mar. 17, 2026
Amount available under revolving line of credit				$ 521,600,000
Unused fee payable percentage				0.25%
Amended and Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Agreement termination date	Mar. 17, 2021

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 2,610,399	$ 2,314,394	$ 2,089,929
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	2,610,399	2,314,394	2,089,929
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	1,330,757	1,126,872	984,609
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	564,671	510,929	452,805
U.S. Facilities [Member] \| Comprehensive Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	419,940	385,635	349,217
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 295,031	283,169	281,158
U.S. Facilities [Member] \| Other [Member]
Disaggregation of Revenue [Line Items]
Revenue		$ 7,789	$ 22,140

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue

12 Months Ended

Dec. 31, 2022

Revenue From Contract With Customer [Abstract]

Revenue

3. Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

As the Company’s performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as the Company’s patients typically are under no obligation to remain admitted in the Company’s facilities.

At December 31, 2022 and 2021, estimated implicit price concessions of $61.4 million and $49.7 million, respectively, had been recorded as reductions to the Company’s accounts receivable balances to enable the Company to record its revenues and accounts receivable at the estimated amounts the Company expected to collect.

The Company disaggregates revenue from contracts with customers by service type and by payor.

The Company’s facilities and services provided by the facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; comprehensive treatment centers (“CTCs”); and residential treatment centers.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities and eating disorder facilities. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Comprehensive treatment centers. CTCs specialize in providing medication-assisted treatment in an outpatient setting to individuals addicted to opioids such as opioid analgesics (prescription pain medications).

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

The table below presents total revenue from continuing operations attributed to each category (in thousands):

	Year Ended December 31,
	2022		2021		2020
Acute inpatient psychiatric facilities	$	1,330,757	$	1,126,872	$	984,609
Specialty treatment facilities		564,671		510,929		452,805
Comprehensive treatment centers		419,940		385,635		349,217
Residential treatment centers		295,031		283,169		281,158
Other		—		7,789		22,140
Revenue	$	2,610,399	$	2,314,394	$	2,089,929

The Company receives payments from the following sources for services rendered in its facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company’s facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the consolidated statements of operations. Bad debt expense for the years ended December 31, 2022, 2021 and 2020 was not significant.

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be estimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s facilities and cost settlement provisions. Management

estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report payables were $13.7 million and $6.5 million as of December 31, 2022 and 2021, respectively, and were included in other current liabilities on the consolidated balance sheet. The net adjustments to estimated cost report settlements resulted in an increase to revenue of $0.1 million for the year ended December 31, 2022, compared to decreases to revenue of $5.4 million and $1.3 million for the years ended December 31, 2021 and 2020, respectively.

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. Such amounts determined to qualify as charity care are not reported as revenue. The cost of providing charity care services were $6.4 million, $3.8 million and $4.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from the Company’s most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

The following table presents revenue by payor type and as a percentage of revenue for continuing operations for the years ended December 31, 2022, 2021 and 2020 (in thousands):

	Year Ended December 31,
	2022					2021					2020
	Amount		%			Amount		%			Amount		%
Commercial	$	788,895		30.2	%	$	684,292		29.6	%	$	596,698		28.5	%
Medicare		394,227		15.1	%		364,598		15.8	%		330,070		15.8	%
Medicaid		1,319,600		50.6	%		1,147,884		49.6	%		1,037,852		49.7	%
Self-Pay		76,050		2.9	%		93,425		4.0	%		98,302		4.7	%
Other		31,627		1.2	%		24,195		1.0	%		27,007		1.3	%
Revenue	$	2,610,399		100.0	%	$	2,314,394		100.0	%	$	2,089,929		100.0	%

Contract liabilities primarily consisted of advances from payors and unearned revenue from CMS’ Accelerated and Advance Payment Program. In April 2020, the Company received approximately $45.2 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. Of the $45.2 million of advance payments received in 2020, the Company repaid approximately $25.1 million of advance payments during 2021 and made additional payments of approximately $20.1 million during the year ended December 31, 2022. Contract liabilities of $6.7 million and $30.4 million are included in other accrued liabilities at December 31, 2022 and 2021, respectively, on the consolidated balance sheet. A summary of the activity in contract liabilities is as follows (in thousands):

Balance at December 31, 2020	$	47,196
Payments received		11,739
Revenue recognized		(3,463	)
Medicare advance repayments		(25,101	)
Balance at December 31, 2021	$	30,371
Payments received		22,914
Revenue recognized		(26,497	)
Medicare advance repayments		(20,135	)
Balance at December 31, 2022	$	6,653

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2022	Dec. 31, 2021	Oct. 14, 2020	Jun. 24, 2020
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Gain (loss) on derivative instruments, tax	$ 0.0	$ 0.1	$ (3.9)
Pension liability adjustment, tax	$ 0.0	$ 0.0	$ (0.8)

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2022 and 2021 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2022		December 31, 2021		December 31, 2022			December 31, 2021
Intangible assets subject to amortization:
Non-compete agreements	$	1,131	$	1,131	$	(1,131	)	$	(1,131	)

Intangible assets not subject to amortization:
Licenses and accreditations		11,512		11,600		—			—
Trade names		45,935		40,435		—			—
Certificates of need		18,594		18,110		—			—
		76,041		70,145		—			—
Total	$	77,172	$	71,276	$	(1,131	)	$	(1,131	)

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	89,913,659	89,028,158
Common stock, shares outstanding	89,913,659	89,028,158

Equity-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	12,700,000
Equity incentive plan available for future grant	3,133,811
Annual increments in employee grants	25.00%
Stock options, contractual term	10 years
Equity-based compensation expense	$ 29,635,000	$ 37,530,000	$ 22,504,000
Unrecognized compensation expense related to unvested options	$ 61,900,000
Vesting period	1 year 4 months 24 days
Warrant outstanding	$ 0
Deferred income tax benefit	16,545,000	11,772,000	53,108,000
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 8,000,000.0	$ 9,600,000	$ 5,500,000
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issuable at the end of the vesting period, percentage	0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of shares issuable at the end of the vesting period, percentage	200.00%

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Carrying Amount [Member] \| New Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Revolving Facility	$ 471,489	$ 584,418
Carrying Amount [Member] \| 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	444,694	443,894
Carrying Amount [Member] \| 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	469,609	468,907
Fair Value [Member] \| New Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	471,489	584,418
Fair Value [Member] \| 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	422,459	466,577
Fair Value [Member] \| 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 433,214	$ 481,802

Variable Interest Entities

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Variable Interest Entities

13. Variable Interest Entities

For legal entities where the Company has a financial relationship, the Company evaluates whether it has a variable interest and determines if the entity is considered a variable interest entity (“VIE”). If the Company concludes an entity is a VIE and the Company is the primary beneficiary, the entity is consolidated. The primary beneficiary analysis is a qualitative analysis based on power and benefits. A reporting entity has a controlling financial interest in a VIE and must consolidate the VIE if it has both power and benefits. It must have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.

At December 31, 2022, the Company operated eight facilities through non-wholly owned subsidiaries. The Company owns between approximately 65% and 86% of the equity interests of these entities, and noncontrolling partners own the remaining equity interests. The Company manages each of these facilities, is responsible for the day to day operations and, therefore, has the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These activities include, but are not limited to, behavioral healthcare services, human resource and employment-related decisions, marketing and finance. The terms of the agreements governing each of the Company’s VIEs prohibit the Company from using the assets of each VIE to satisfy the obligations of other entities. Consolidated assets at December 31, 2022 and 2021 include total assets of variable interest entities of $434.2 million and $320.6 million, respectively, which cannot be used to settle the obligations of other entities. Consolidated liabilities at December 31, 2022 and 2021 include total liabilities of variable interest entities of $24.4 million and $24.1 million, respectively.

The consolidated VIEs assets and liabilities in the Company’s consolidated balance sheets are shown below (in thousands):

	December 31,
	2022		2021
Cash and cash equivalents	$	32,478	$	26,360
Accounts receivable, net		23,789		20,144
Other current assets		2,561		1,304
Total current assets		58,828		47,808
Property and equipment, net		313,358		220,793
Goodwill		39,564		34,945
Intangible assets, net		16,139		10,490
Operating lease right-of-use assets		6,284		6,603
Total assets	$	434,173	$	320,639
Accounts payable	$	4,650	$	3,690
Accrued salaries and benefits		6,866		5,656
Current portion of operating lease liabilities		233		197
Other accrued liabilities		6,179		6,818
Total current liabilities		17,928		16,361
Operating lease liabilities		6,433		6,666
Other liabilities		—		1,083
Total liabilities	$	24,361	$	24,110

Noncontrolling Interests (Tables)

12 Months Ended

Dec. 31, 2022

Noncontrolling Interest [Abstract]

Summary of Redeemable Noncontrolling Interests

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2021	$	55,315
Contributions from noncontrolling partners in joint ventures		6,734
Net income attributable to noncontrolling interests		4,927
Distributions to noncontrolling partners in joint ventures		(1,588	)
Balance at December 31, 2021		65,388
Contributions from noncontrolling partners in joint ventures		21,162
Net income attributable to noncontrolling interests		6,894
Acquisition of ownership interests from noncontrolling partners		(4,183	)
Distributions to noncontrolling partners in joint ventures		(1,004	)
Balance at December 31, 2022	$	88,257

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities:
Net income (loss)	$ 280,033	$ 195,562	$ (669,199)
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities:
Depreciation and amortization	117,769	106,717	95,256
Amortization of debt issuance costs	3,261	4,071	12,636
Equity-based compensation expense	29,635	37,530	22,504
Deferred income taxes	16,545	11,772	53,108
Loss from discontinued operations, net of taxes		12,641	812,390
Debt extinguishment costs		24,650	7,233
Loss on impairment		24,293	4,751
Other	2,680	491	1,041
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(41,978)	2,448	15,340
Other current assets	(17,626)	1,968	9,675
Other assets	2,252	(10,770)	1,519
Accounts payable and other accrued liabilities	5,174	6,164	41,910
Accrued salaries and benefits	6,804	9,755	(10,001)
Other liabilities	15,090	(14,940)	18,082
Government relief funds	(39,070)	(38,128)	86,599
Net cash provided by continuing operating activities	380,569	374,224	502,844
Net cash provided by discontinued operating activities		253	155,963
Net cash provided by operating activities	380,569	374,477	658,807
Investing activities:
Cash paid for acquisitions, net of cash acquired	(9,507)	(139,015)
Cash paid for capital expenditures	(296,149)	(244,811)	(224,964)
Proceeds from U.K. Sale		1,511,020
Settlement of foreign currency derivatives		(84,795)
Proceeds from sale of property and equipment	7,074	3,493	92
Cash paid for purchase of finance lease		(31,401)
Other	(7,248)	(1,394)	(13,365)
Net cash (used in) provided by continuing investing activities	(305,830)	1,013,097	(238,237)
Net cash used in discontinued investing activities			(43,602)
Net cash (used in) provided by investing activities	(305,830)	1,013,097	(281,839)
Financing activities:
Borrowings on long-term debt		425,000	925,000
Borrowings on revolving credit facility		500,000	100,000
Principal payments on revolving credit facility	(95,000)	(330,000)	(100,000)
Principal payments on long-term debt	(18,594)	(7,969)	(41,291)
Repayment of long-term debt		(2,227,935)	(909,785)
Payment of debt issuance costs		(7,964)	(18,295)
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(6,179)	16,295	184
Contributions from noncontrolling partners in joint ventures	15,362	4,536
Distributions to noncontrolling partners in joint ventures	(1,004)	(1,588)	(916)
Acquisition of ownership interests from noncontrolling partners	(5,540)
Other	52	(6,900)	(3,146)
Net cash used in continuing financing activities	(110,903)	(1,636,525)	(48,249)
Net cash used in discontinued financing activities			(3,250)
Net cash used in financing activities	(110,903)	(1,636,525)	(51,499)
Effect of exchange rate changes on cash		4,067	4,087
Net (decrease) increase in cash and cash equivalents, including cash classified within current assets held for sale	(36,164)	(244,884)	329,556
Less: cash classified within current assets held for sale			(75,051)
Net (decrease) increase in cash and cash equivalents	(36,164)	(244,884)	254,505
Cash and cash equivalents at beginning of the period	133,813	378,697	124,192
Cash and cash equivalents at end of the period	97,649	133,813	378,697
Supplemental Cash Flow Information:
Cash paid for interest	65,687	93,669	137,578
Cash paid (received) for income taxes	86,195	79,304	(16,486)
Effect of acquisitions:
Assets acquired, excluding cash	10,756	176,365	20,200
Liabilities assumed	(1,249)	(37,350)	(53)
Redeemable noncontrolling interest resulting from an acquisition			$ (20,147)
Cash paid for acquisitions, net of cash acquired	$ 9,507	$ 139,015

Summary of Significant Accounting Policies - Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 27,052	$ 22,292
Other receivables	15,371	10,786
Workers’ compensation deposits – current portion	12,000	12,000
Insurance receivable - current portion	10,158	10,807
Assets held for sale	8,347	15,808
Income taxes receivable	5,767	1,523
Inventory	5,087	4,786
Other	2,255	1,884
Other current assets	$ 86,037	$ 79,886

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2022	Feb. 28, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Trading Symbol	ACHC
Entity Registrant Name	ACADIA HEALTHCARE COMPANY, INC.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		91,314,616
Entity Public Float			$ 6.0
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Auditor Name	Ernst & Young LLP
Auditor Location	Nashville, Tennessee
Auditor Firm ID	42
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for its 2023 annual meeting of stockholders to be held on May 18, 2023 are incorporated by reference into Part III of this Form 10-K.

Revenue - Summary of the Activity in Unearned Revenue in U.S. Facilities (Detail) - U.S. Facilities [Member] - Unearned Revenue [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 30,371	$ 47,196
Payments received	22,914	11,739
Revenue recognized	(26,497)	(3,463)
Ending Balance	6,653	30,371
Medicare [Member]
Disaggregation of Revenue [Line Items]
Medicare advance repayments	$ (20,135)	$ (25,101)

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance	1,106,069	1,510,306	1,360,068
Options granted	334,260	324,320	507,600
Options exercised	(285,577)	(558,322)	(68,700)
Options cancelled	(175,475)	(170,235)	(288,662)
Options outstanding, Ending balance	979,277	1,106,069	1,510,306
Options exercisable, Ending balance	301,827
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 42.07	$ 37.56	$ 39.40
Options granted, Weighted Average Exercise Price	55.73	57.53	33.13
Options exercised, Weighted Average Exercise Price	40.66	39.45	29.15
Options cancelled, Weighted Average Exercise Price	46.98	40.08	39.67
Options outstanding, Weighted Average Exercise Price, Ending balance	46.27	$ 42.07	$ 37.56
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 41.43
Options outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 8 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	5 years 8 months 8 days
Options outstanding, Aggregate Intrinsic Value	$ 35,303
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 12,341

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Equity-based compensation expense	$ 29,635	$ 37,530	$ 22,504

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2020, 2021 and 2022 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2020		1,360,068		$	39.40
Options granted		507,600			33.13
Options exercised		(68,700	)		29.15
Options cancelled		(288,662	)		39.67
Options outstanding at December 31, 2020		1,510,306			37.56
Options granted		324,320			57.53
Options exercised		(558,322	)		39.45
Options cancelled		(170,235	)		40.08
Options outstanding at December 31, 2021		1,106,069			42.07
Options granted		334,260			55.73
Options exercised		(285,577	)		40.66
Options cancelled		(175,475	)		46.98
Options outstanding at December 31, 2022		979,277		$	46.27		7.44	$	35,303
Options exercisable at December 31, 2022		301,827		$	41.43		5.69	$	12,341

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2022, 2021 and 2020:

	Year Ended December 31,
	2022			2021			2020
Weighted average grant-date fair value of options	$	20.72		$	20.64		$	12.37
Risk-free interest rate		2.0	%		0.9	%		1.6	%
Expected volatility		39	%		40	%		41	%
Expected life (in years)		5.0			5.0			5.0

Restricted Stock Activity

Restricted stock activity during 2020, 2021 and 2022 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2020		805,136		$	34.14
Granted		637,312			25.82
Cancelled		(129,683	)		34.56
Vested		(289,769	)		35.88
Unvested at December 31, 2020		1,022,996		$	28.41
Granted		352,430			58.32
Cancelled		(82,751	)		39.63
Vested		(366,048	)		30.81
Unvested at December 31, 2021		926,627		$	37.84
Granted		650,396			64.65
Cancelled		(145,205	)		49.03
Vested		(386,616	)		32.64
Unvested at December 31, 2022		1,045,202		$	54.89

Restricted Stock Unit Activity

Restricted stock unit activity during 2020, 2021 and 2022 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2020		447,357		$	38.89
Granted		583,680			10.60
Performance adjustment		117,772			13.50
Cancelled		(63,056	)		43.35
Vested		(12,691	)		42.09
Unvested at December 31, 2020		1,073,062		$	20.15
Granted		149,416			61.52
Performance adjustment		465,993			25.49
Cancelled		—			—
Vested		(184,051	)		42.30
Unvested at December 31, 2021		1,504,420		$	23.20
Granted		105,311			73.96
Performance adjustment		182,543			33.05
Cancelled		—			—
Vested		(518,474	)		43.16
Unvested at December 31, 2022		1,273,800		$	20.69

Equity

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Equity

15. Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The board of directors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders.

Common Stock

The Company’s amended and restated certificate of incorporation provides that up to 180,000,000 shares of common stock may be issued. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of

the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the New Credit Facility imposes restrictions on the Company’s ability to pay dividends.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Revenue - Schedule of Revenue and Percentage Generated by Each Payor Type in U.S Facilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 2,610,399	$ 2,314,394	$ 2,089,929
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 2,610,399	$ 2,314,394	$ 2,089,929
Revenue, Percentage	100.00%	100.00%	100.00%
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 788,895	$ 684,292	$ 596,698
Revenue, Percentage	30.20%	29.60%	28.50%
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 394,227	$ 364,598	$ 330,070
Revenue, Percentage	15.10%	15.80%	15.80%
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 1,319,600	$ 1,147,884	$ 1,037,852
Revenue, Percentage	50.60%	49.60%	49.70%
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 76,050	$ 93,425	$ 98,302
Revenue, Percentage	2.90%	4.00%	4.70%
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 31,627	$ 24,195	$ 27,007
Revenue, Percentage	1.20%	1.00%	1.30%

- Definition

+ References

+ Details

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	21 years 10 months 24 days	22 years 10 months 24 days
Operating lease, weighted average remaining term (years)	8 years 4 months 24 days	9 years 1 month 6 days
Finance lease, weighted average discount rate percent	5.10%	5.10%
Operating lease, weighted average discount rate percent	5.00%	5.10%

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain (Loss) on derivative instruments, tax	$ 0.0	$ 0.1	$ (3.9)
Pension liability adjustment, tax	$ 0.0	$ 0.0	$ (0.8)

Acquisitions - Additional Information (Detail) $ in Millions		12 Months Ended
	Dec. 31, 2021 USD ($) Bed Hospital Location	Dec. 31, 2022 USD ($) Bed	Dec. 31, 2021 USD ($) Bed
Business Acquisition [Line Items]
Number of beds \| Bed		11,000
Tax deductible		$ 9.5	$ 56.1
CenterPointe Behavioral Health System, LLC [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration	$ 140.0
Revolving Facility	$ 70.0		$ 70.0
Number of acute inpatient hospitals \| Hospital	4
Number of beds \| Bed	306		306
Number of outpatient locations \| Location	10

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Long-Term Debt (Other) - Summary of Aggregate Maturities of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 21,250
2024	29,219
2025	39,844
2026	383,125
Thereafter	925,000
Total	$ 1,398,438

Long-Term Debt (5.500% Senior Notes due 2028) - Additional Information (Detail) - 5.500% Senior Notes due 2028 [Member] - USD ($)		12 Months Ended
	Jun. 24, 2020	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Issued Senior Notes	$ 450,000,000.0
Debt instrument interest rate	5.50%	5.50%	5.50%
Debt instrument maturity date	Jul. 01, 2028
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Combinations [Abstract]
Management transition costs	$ 11,575
Termination and restructuring costs	6,476	$ 5,343	$ 3,468
Legal, accounting and other acquisition-related costs	5,741	7,435	8,252
Transaction-related expenses	$ 23,792	$ 12,778	$ 11,720

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	0.1	0.3	1.9

Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2020	$	(434,633	)	$	24,958		$	(5,209	)	$	(414,884	)
Foreign currency translation gain (loss)		61,532			—			(285	)		61,247
Loss on derivative instruments, net of tax of $(3.9) million		—			(11,272	)		—			(11,272	)
Pension liability adjustment, net of tax of $(0.8) million		—			—			(6,456	)		(6,456	)
Balance at December 31, 2020		(373,101	)		13,686			(11,950	)		(371,365	)
Foreign currency translation gain (loss)		(4,293	)		—			33			(4,260	)
Gain on derivative instruments, net of tax of $0.1 million		—			19			—			19
U.K. Sale		377,394			(13,705	)		11,917			375,606
Balance at December 31, 2021	$	—		$	—		$	—		$	—

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2022, 2021 and 2020 (in thousands, except per share amounts):

	Year Ended December 31,
	2022		2021			2020
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	273,139	$	203,276		$	140,258
Loss from discontinued operations		—		(12,641	)		(812,390	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	273,139	$	190,635		$	(672,132	)
Denominator:
Weighted average shares outstanding for basic earnings per share		89,680		88,769			87,875
Effects of dilutive instruments		1,875		2,024			720
Shares used in computing diluted earnings per common share		91,555		90,793			88,595

Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	3.05	$	2.29		$	1.60
Loss from discontinued operations		—		(0.14	)		(9.25	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	3.05	$	2.15		$	(7.65	)

Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	2.98	$	2.24		$	1.58
Loss from discontinued operations		—		(0.14	)		(9.17	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	2.98	$	2.10		$	(7.59	)

Acquisitions

12 Months Ended

Dec. 31, 2022

Business Combinations [Abstract]

Acquisitions

5. Acquisitions

The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On November 7, 2022, the Company acquired four CTCs located in Georgia from Brand New Start Treatment Centers.

On December 31, 2021, the Company acquired the equity of CenterPointe Behavioral Health System, LLC and certain related entities (“CenterPointe”) for cash consideration of approximately $140 million. The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Revolving Facility. At the time of the acquisition, CenterPointe operated four acute inpatient hospitals with 306 beds and ten outpatient locations primarily in Missouri.

The fair values of assets acquired and liabilities assumed in the CenterPointe acquisition were as follows (in thousands):

Cash	$	5,640
Accounts receivable, net		9,358
Other current assets		1,981
Property and equipment		35,227
Goodwill		105,883
Intangible assets		825
Deferred tax assets		1,573
Operating lease right-of-use assets		29,245
Total assets acquired		189,732
Accounts payable		3,820
Accrued salaries and benefits		3,585
Current portion of operating lease liabilities		2,820
Other accrued liabilities		4,326
Deferred tax liability		1,805
Operating lease liabilities		27,850
Total liabilities assumed		44,206
Net assets acquired	$	145,526

The qualitative factors comprising the goodwill acquired in the CenterPointe acquisition include the value of the business and efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance and applying best practices.

Goodwill

The following table summarizes changes in goodwill for the years ended December 31, 2022 and 2021 (in thousands):

Balance at January 1, 2021	$	2,105,264
Increase from acquisitions		97,122
2021 dispositions		(2,449	)
Balance at December 31, 2021		2,199,937
Increase from acquisitions		9,488
Adjustments related to 2021 acquisitions		8,761
Increase from contributions of redeemable noncontrolling interests		4,619
Balance at December 31, 2022	$	2,222,805

Of the increases to goodwill from acquisitions in 2022 and 2021, the Company expects $9.5 million and $56.1 million to be tax-deductible for the years ended December 31, 2022 and 2021, respectively.

Transaction-related expenses

	Year Ended December 31,
	2022		2021		2020
Management transition costs	$	11,575	$	—	$	—
Termination and restructuring costs		6,476		5,343		3,468
Legal, accounting and other acquisition-related costs		5,741		7,435		8,252
	$	23,792	$	12,778	$	11,720

Acquisitions - Summary of Changes in Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Business Combinations [Abstract]
Goodwill balance			$ 2,199,937	$ 2,105,264
Increase from acquisitions			9,488	97,122
2021 dispositions	$ (700)	$ (1,800)		(2,449)
Adjustments related to 2021 acquisitions			8,761
Increase from contributions of redeemable noncontrolling interests			4,619
Goodwill balance	$ 2,199,937		$ 2,222,805	$ 2,199,937

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes		$ 275,000,000.0	$ 375,000,000.0
Debt instrument interest rate		5.625%	5.625%
Senior Notes		$ 650,000,000.0
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year
Term loan remaining balance due date	Mar. 17, 2021

Variable Interest Entities - Schedule of Consolidated VIEs Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 97,649	$ 133,813
Accounts receivable, net	322,439	281,332
Other current assets	86,037	79,886
Total current assets	506,125	495,031
Property and equipment, net	1,952,045	1,771,159
Goodwill	2,222,805	2,199,937	$ 2,105,264
Intangible assets, net	76,041	70,145
Operating lease right-of-use assets	135,238	133,761
Total assets	4,987,901	4,768,078
Accounts payable	104,723	98,575
Accrued salaries and benefits	125,298	137,845
Current portion of operating lease liabilities	26,463	23,348
Other accrued liabilities	110,592	126,499
Total current liabilities	388,326	404,861
Operating lease liabilities	116,429	116,841
Other liabilities	125,033	110,505
Total liabilities	2,086,917	2,185,201
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	32,478	26,360
Accounts receivable, net	23,789	20,144
Other current assets	2,561	1,304
Total current assets	58,828	47,808
Property and equipment, net	313,358	220,793
Goodwill	39,564	34,945
Intangible assets, net	16,139	10,490
Operating lease right-of-use assets	6,284	6,603
Total assets	434,173	320,639
Accounts payable	4,650	3,690
Accrued salaries and benefits	6,866	5,656
Current portion of operating lease liabilities	233	197
Other accrued liabilities	6,179	6,818
Total current liabilities	17,928	16,361
Operating lease liabilities	6,433	6,666
Other liabilities		1,083
Total liabilities	$ 24,361	$ 24,110

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Examination [Line Items]
Provision for income taxes	$ 94,110	$ 67,557	$ 40,606
Effective tax rates	25.20%	24.50%	22.10%
Valuation allowance against deferred tax assets	$ 217,705	$ 217,325
Operating loss carryforwards expiration end year	2036
Federal net operating loss carryforwards	$ 0	0
Foreign net operating loss carryforwards	100	100
State net operating loss carry forwards	$ 191,500	227,300
Operating loss carryforwards expiration start year	2023
Expiration of State tax credits	2030
State tax credits	$ 200
Income taxes receivable	28,900	24,600
Income tax payable included in other accrued liabilities	1,338	5,540
Unrecognized tax benefits	$ 0	0	$ 2,060
Earliest Tax Year [Member] \| Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2019
Latest Tax Year [Member] \| Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2021
Other Assets [Member]
Income Tax Examination [Line Items]
Income taxes receivable	$ 23,100	23,100
Other Current Assets [Member]
Income Tax Examination [Line Items]
Income taxes receivable	$ 5,800	$ 1,500
Foreign Tax Authority [Member]
Income Tax Examination [Line Items]
Operating loss carryforwards expiration end year	2026
Period of examination by internal revenue service minimum	2018
Period of examination by internal revenue service maximum	2021
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2017
Period of examination by internal revenue service maximum	2021

Leases - Schedule of Undiscounted Future Cash Flows for Finance and Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finance Leases
2023	$ 990
2024	1,007
2025	1,089
2026	1,180
2027	1,089
Thereafter	21,821
Total minimum lease payments	27,176
Less: amount of lease payments representing interest	15,328
Present value of future minimum lease payments	11,848
Less: Current portion of lease liabilities	990	$ 990
Noncurrent lease liabilities	10,858	10,807
Operating Leases
2023	32,818
2024	29,568
2025	25,146
2026	19,251
2027	12,380
Thereafter	62,653
Total minimum lease payments	181,816
Less: amount of lease payments representing interest	38,924
Present value of future minimum lease payments	142,892
Current portion of operating lease liabilities	26,463	23,348
Operating lease liabilities	$ 116,429	$ 116,841

Income Taxes - Components of Provision for Income Taxes From Continuing operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 63,041	$ 48,292	$ (18,215)
State	13,769	6,715	4,981
Foreign	755	778	732
Total current	77,565	55,785	(12,502)
Deferred:
Federal	9,808	13,339	46,442
State	6,377	(1,892)	564
Foreign	360	325	6,102
Total deferred provision	16,545	11,772	53,108
Provision for income taxes	$ 94,110	$ 67,557	$ 40,606

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		12 Months Ended
	Jul. 01, 2014	Dec. 31, 2022
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000.0
Debt instrument interest rate	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year
Term loan remaining balance due date		Jun. 24, 2020

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

20. Commitments and Contingencies

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. On September 30, 2022, the court entered an order certifying a class consisting of all persons who purchased or otherwise acquired the common stock of the Company between April 30, 2014 and November 15, 2018. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 16, 2021, the court entered an order staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Pfenning v. Jacobs, et al., Case No. 2020-0915-JRS, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. On February 24, 2021, a purported stockholder filed a fourth derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Solak v. Jacobs, et al., Case No. 2021-0163, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and insider selling. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

In the fall of 2017, the Office of Inspector General (“OIG”) issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

U.K. Sale (Tables)

12 Months Ended

Dec. 31, 2022

Discontinued Operations And Disposal Groups [Abstract]

Schedule of Financial Condition, Results of Operations and Cash Flows of U.K. Operations as Discontinued Operations

For the years ended December 31, 2021 and 2020, results of operations of the U.K. operations were as follows (in thousands):

	Year Ended December 31,
	2021			2020
Revenue	$	62,520		$	1,119,768
Salaries, wages and benefits		35,937			632,134
Professional fees		6,815			127,291
Supplies		2,217			38,285
Rents and leases		2,509			47,748
Other operating expenses		6,682			113,534
Depreciation and amortization		—			74,935
Interest expense, net		10			(417	)
Loss on sale		13,490			867,324
Loss on impairment		—			20,239
Transaction-related expenses		6,265			8,719
Total expenses		73,925			1,929,792
Loss from discontinued operations before income taxes		(11,405	)		(810,024	)
Provision for income taxes		1,236			2,366
Loss from discontinued operations	$	(12,641	)	$	(812,390	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Accounts receivable, net		$ (41,978)	$ 2,448	$ 15,340
Cost report payables		13,700	6,500
Net adjustments to estimated cost report settlements resulted in (decreases) increases to revenue		100	(5,400)	(1,300)
Costs of providing charity care services		6,400	3,800	$ 4,400
CARES Act [Member] \| Medicare [Member]
Disaggregation of Revenue [Line Items]
Repayment of advanced payments			25,100
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member]
Disaggregation of Revenue [Line Items]
Amount of advance payment received	$ 45,200
Repayment of advanced payments		20,100	25,100
Repayment of advanced payments description	In April 2020, the Company received approximately $45.2 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. Of the $45.2 million of advance payments received in 2020, the Company repaid approximately $25.1 million of advance payments during 2021 and made additional payments of approximately $20.1 million during the year ended December 31, 2022.
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member] \| Other Accrued Liabilities [Member]
Disaggregation of Revenue [Line Items]
Contract liabilities		6,700	30,400
Accounting Standards Update 2014-09
Disaggregation of Revenue [Line Items]
Accounts receivable, net		$ 61,400	$ 49,700

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	(Accumulated Deficit) Retained Earnings [Member]
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	$ 2,557,642	$ (414,884)	$ 361,746
Balance, shares at Dec. 31, 2019		87,715,000
Common stock issued under stock incentive plans	$ 2,027	$ 3	2,024
Common stock issued under stock incentive plans, shares	68,700	309,000
Repurchase of shares for payroll tax witholdings, net of proceeds from stock option exercises	$ (1,843)		(1,843)
Equity-based compensation expense	22,504		22,504
Other comprehensive income	43,519			43,519
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	(672,132)				(672,132)
Balance at Dec. 31, 2020	1,899,456	$ 880	2,580,327	(371,365)	(310,386)
Balance, shares at Dec. 31, 2020		88,024,000
Common stock issued under stock incentive plans	$ 22,029	$ 10	22,019
Common stock issued under stock incentive plans, shares	558,322	1,004,000
Repurchase of shares for payroll tax witholdings, net of proceeds from stock option exercises	$ (5,734)		(5,734)
Equity-based compensation expense	37,530		37,530
Other comprehensive income	371,365			$ 371,365
Other	2,208		2,208
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	190,635				190,635
Balance at Dec. 31, 2021	$ 2,517,489	$ 890	2,636,350		(119,751)
Balance, shares at Dec. 31, 2021	89,028,158	89,028,000
Common stock issued under stock incentive plans	$ 11,613	$ 9	11,604
Common stock issued under stock incentive plans, shares	285,577	886,000
Repurchase of shares for payroll tax witholdings, net of proceeds from stock option exercises	$ (17,792)		(17,792)
Equity-based compensation expense	29,635		29,635
Other	(1,357)		(1,357)
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	273,139				273,139
Balance at Dec. 31, 2022	$ 2,812,727	$ 899	$ 2,658,440		$ 153,388
Balance, shares at Dec. 31, 2022	89,913,659	89,914,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Long-Term Debt (Other Long-term Debt) - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Debt Disclosure [Abstract]
Repayments of other long-term debt	$ 3.3

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 1,899,456	$ 2,505,381
Foreign currency translation gain (loss)	(4,260)	61,247
Gain (loss) on derivative instruments, net of tax of $0.0 million, $0.1 million and $(3.9) million, respectively	19	(11,272)
Pension liability adjustment, net of tax of $0.0 million, $0.0 million and $(0.8) million, respectively		(6,456)
U.K. Sale	375,606
Balance	2,517,489	1,899,456
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(373,101)	(434,633)
Foreign currency translation gain (loss)	(4,293)	61,532
U.K. Sale	377,394
Balance		(373,101)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	13,686	24,958
Gain (loss) on derivative instruments, net of tax of $0.0 million, $0.1 million and $(3.9) million, respectively	19	(11,272)
U.K. Sale	(13,705)
Balance		13,686
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(11,950)	(5,209)
Foreign currency translation gain (loss)	33	(285)
Pension liability adjustment, net of tax of $0.0 million, $0.0 million and $(0.8) million, respectively		(6,456)
U.K. Sale	11,917
Balance		(11,950)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (371,365)	(414,884)
Balance		$ (371,365)

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finance lease costs:
Depreciation of leased assets	$ 378	$ 378	$ 868
Interest of lease liabilities	1,041	2,174	3,214
Total finance lease costs	1,419	2,552	4,082
Operating lease costs	34,349	28,233	27,050
Variable lease costs	3,129	2,488	2,501
Short term lease costs	2,605	3,257	3,558
Other lease costs	5,379	4,541	4,253
Total rents and leases	45,462	38,519	37,362
Total lease costs	$ 46,881	$ 41,071	$ 41,444

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	1,504,420	1,073,062	447,357
Granted, Number of Units	105,311	149,416	583,680
Performance adjustment, Number of Units	182,543	465,993	117,772
Cancelled, Number of Units			(63,056)
Vested, Number of Units	(518,474)	(184,051)	(12,691)
Unvested, Number of Shares/Units, Ending balance	1,273,800	1,504,420	1,073,062
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 23.20	$ 20.15	$ 38.89
Granted, Weighted Average Grant-Date Fair Value	73.96	61.52	10.60
Performance adjustment, Weighted Average Grant-Date Fair Value	33.05	25.49	13.50
Cancelled, Weighted Average Grant-Date Fair Value			43.35
Vested, Weighted Average Grant-Date Fair Value	43.16	42.30	42.09
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 20.69	$ 23.20	$ 20.15

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 20.72	$ 20.64	$ 12.37
Risk-free interest rate	2.00%	0.90%	1.60%
Expected volatility	39.00%	40.00%	41.00%
Expected life (in years)	5 years	5 years	5 years

Fair Value Measurements

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

19. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s New Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes at December 31, 2022 and 2021 were as follows (in thousands):

	Carrying Amount				Fair Value
	December 31,				December 31,
	2022		2021		2022		2021
New Credit Facility	$	471,489	$	584,418	$	471,489	$	584,418
5.500% Senior Notes due 2028	$	444,694	$	443,894	$	422,459	$	466,577
5.000% Senior Notes due 2029	$	469,609	$	468,907	$	433,214	$	481,802

The Company’s New Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Oct. 14, 2020	Jun. 24, 2020
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
Senior notes maturity year	2028	2028
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%
Senior notes maturity year	2029	2029

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Facility Bed State	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Accounting Policies [Abstract]
Number of facilities \| Facility	250
Number of beds \| Bed	11,000
Number of operating states \| State	39
General and administrative expenses \| $	$ 124.3	$ 108.2	$ 97.8

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Cash and Cash Equivalents

Insurance

Property and Equipment and Other Long-Lived Assets

Goodwill and Indefinite-Lived Intangible Assets

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2022		2021
Prepaid expenses	$	27,052	$	22,292
Other receivables		15,371		10,786
Workers’ compensation deposits – current portion		12,000		12,000
Insurance receivable – current portion		10,158		10,807
Assets held for sale		8,347		15,808
Income taxes receivable		5,767		1,523
Inventory		5,087		4,786
Other		2,255		1,884
Other current assets	$	86,037	$	79,886

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2022		2021
Accrued expenses	$	26,699	$	26,791
Accrued interest		17,596		17,418
Cost report payable		13,738		6,487
Insurance liability – current portion		12,128		11,923
Accrued property taxes		9,009		8,375
Government relief funds		8,975		8,550
Contract liabilities		6,653		30,371
Income taxes payable		1,338		5,540
Finance lease liabilities		990		990
Other		13,466		10,054
Other accrued liabilities	$	110,592	$	126,499

Stock Compensation

Earnings Per Share

Income Taxes

Recent Accounting Pronouncements

Leases - Additional Information (Detail)	12 Months Ended
Leases - Additional Information (Detail)	Dec. 31, 2022
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	5 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	30 years
Copiers and Equipment [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	1 year
Copiers and Equipment [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	3 years

The CARES Act

12 Months Ended

Dec. 31, 2022

Extraordinary And Unusual Items [Abstract]

The CARES Act

10. The CARES Act

As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the U.S. government announced it would offer $100 billion of relief to eligible healthcare providers. On April 24, 2020, then President Trump signed into law the Paycheck Protection Program and Health Care Enhancement Act (the “PPP Act”). Among other things, the PPP Act allocates $75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the PPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. The Company accounts for government grants by analogizing to the grant model in accordance with International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, and as such, has recognized income from grants in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. The Company recognizes grants once both of the following conditions are met: (i) the Company is able to comply with the relevant terms and conditions of the grant and (ii) the grant will be received.

During 2020, the Company participated in certain relief programs offered through the CARES Act, including receipt of approximately $34.9 million relating to the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund. During the fourth quarter of 2020, the Company recorded approximately $32.8 million of income from provider relief fund related to PHSSE Fund funds received in 2020.

In 2021, the Company received $24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, the Company recorded $17.9 million of income from provider relief fund related to the funds received. During the year ended December 31, 2022, the Company received $7.7 million of additional funds from the PHSSE Fund and $14.2 million from the American Rescue Plan (“ARP”) Rural Payments for Hospitals. During the year ended December 31, 2022, the Company recorded $21.5 million of income from provider relief fund related to PHSSE Fund and ARP funds received. The remaining unrecognized funds of $9.0 million are included in other accrued liabilities on the consolidated balance sheet at December 31, 2022. The Company continues to evaluate its compliance with the terms and conditions to, and the financial impact of, the additional funds received, including potential repayment of the remaining balance.

Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund funds and agree to the terms and conditions of payment. Under the terms and conditions for receipt of the payment, the Company was allowed to use the funds to cover lost revenues and healthcare costs related to COVID-19, and the Company was required to properly and fully document the use of these funds to the U.S. Department of Health and Human Services (“HHS”). The reporting of the funds is subject to future audit for compliance with the terms and conditions. The Company recognized Provider Relief Fund funds to the extent it had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions. The grant income associated with the COVID-19 expenses and lost revenues incurred during the years ended December 31, 2022, 2021 and 2020 is reflected as income from provider relief fund in the Company’s consolidated statements of operations.

During 2020, the Company applied for and received approximately $45.2 million of payments from the CMS Accelerated and Advance Payment Program. Of the $45.2 million of advance payments received in 2020, the Company repaid approximately $25.1 million of advance payments during 2021 and made additional repayments of approximately $20.1 million during the year ended December 31, 2022.

In addition, the Company received a 2% increase in facilities’ Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020, to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.

The CARES Act also provides for certain federal income and other tax changes. The Company received a cash benefit of approximately $39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. The Company repaid half of the $39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter 2022 to eliminate the liability. The payroll tax deferral at December 31, 2021 was included in accrued salaries and benefits on the consolidated balance sheet.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 97,649	$ 133,813
Accounts receivable, net	322,439	281,332
Other current assets	86,037	79,886
Total current assets	506,125	495,031
Property and equipment, net	1,952,045	1,771,159
Goodwill	2,222,805	2,199,937
Intangible assets, net	76,041	70,145
Deferred tax assets	2,950	3,080
Operating lease right-of-use assets	135,238	133,761
Other assets	92,697	94,965
Total assets	4,987,901	4,768,078
Current liabilities:
Current portion of long-term debt	21,250	18,594
Accounts payable	104,723	98,575
Accrued salaries and benefits	125,298	137,845
Current portion of operating lease liabilities	26,463	23,348
Other accrued liabilities	110,592	126,499
Total current liabilities	388,326	404,861
Long-term debt	1,364,541	1,478,626
Deferred tax liabilities	92,588	74,368
Operating lease liabilities	116,429	116,841
Other liabilities	125,033	110,505
Total liabilities	2,086,917	2,185,201
Redeemable noncontrolling interests	88,257	65,388
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 89,913,659 and 89,028,158 issued and outstanding as of December 31, 2022 and 2021, respectively	899	890
Additional paid-in capital	2,658,440	2,636,350
Retained earnings (accumulated deficit)	153,388	(119,751)
Total equity	2,812,727	2,517,489
Total liabilities and equity	$ 4,987,901	$ 4,768,078

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 76,041	$ 70,145
Total	77,172	71,276
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(1,131)	(1,131)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	11,512	11,600
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	45,935	40,435
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	18,594	18,110
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,131
Intangible assets subject to amortization, Accumulated Amortization	$ (1,131)	$ (1,131)

U.K. Sale - Result of Operation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations	$ (12,641)	$ (812,390)
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	62,520	1,119,768
Salaries, wages and benefits	35,937	632,134
Professional fees	6,815	127,291
Supplies	2,217	38,285
Rents and leases	2,509	47,748
Other operating expenses	6,682	113,534
Depreciation and amortization		74,935
Interest expense, net	10	(417)
Loss on sale	13,490	867,324
Loss on impairment		20,239
Transaction-related expenses	6,265	8,719
Total expenses	73,925	1,929,792
Loss from discontinued operations before income taxes	(11,405)	(810,024)
Provision for income taxes	1,236	2,366
Loss from discontinued operations	$ (12,641)	$ (812,390)

Financial Information Combined Wholly-Owned Subsidiaries

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information Combined Wholly-Owned Subsidiaries

22. Financial Information Combined Wholly-Owned Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 5.500% Senior Notes and the 5.000% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the New Credit Facility. Summarized financial information presented below is consistent with the consolidated financial statements of the Company, except transactions between combining entities have been eliminated. Financial information for the combined non-guarantor entities has been excluded. Presented below is financial information for the combined wholly-owned subsidiary guarantors at December 31, 2022 and 2021, and for the year ended December 31, 2022. The summarized balance sheet information at December 31, 2021, has been adjusted to reclassify certain wholly-owned subsidiaries as non-guarantor entities.

Summarized balance sheet information (in thousands):

	December 31,
	2022		2021
Current assets	$	396,553	$	349,250
Property and equipment, net		1,517,893		1,166,409
Goodwill		2,105,227		2,086,978
Total noncurrent assets		3,921,336		3,527,700

Current liabilities		345,606		340,514
Long-term debt		1,364,541		1,478,626
Total noncurrent liabilities		1,629,750		1,688,326
Redeemable noncontrolling interests		—		—
Total equity		2,342,533		1,848,110

Summarized operating results information (in thousands):

	For the Year Ended December 31, 2022
Revenue	$	2,299,562
Income from continuing operations before income taxes		325,309
Net income		244,148
Net income attributable to Acadia Healthcare Company, Inc.		244,148

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,608,619	$ 2,312,285
Less: accumulated depreciation	(656,574)	(541,126)
Property and equipment, net	1,952,045	1,771,159
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	169,137	154,376
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,797,809	1,683,560
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	292,200	253,100
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 349,473	$ 221,249

Financial Information Combined Wholly-Owned Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summarized Balance Sheet

Summarized balance sheet information (in thousands):

	December 31,
	2022		2021
Current assets	$	396,553	$	349,250
Property and equipment, net		1,517,893		1,166,409
Goodwill		2,105,227		2,086,978
Total noncurrent assets		3,921,336		3,527,700

Current liabilities		345,606		340,514
Long-term debt		1,364,541		1,478,626
Total noncurrent liabilities		1,629,750		1,688,326
Redeemable noncontrolling interests		—		—
Total equity		2,342,533		1,848,110

Summarized Statements of Income (Loss)

Summarized operating results information (in thousands):

	For the Year Ended December 31, 2022
Revenue	$	2,299,562
Income from continuing operations before income taxes		325,309
Net income		244,148
Net income attributable to Acadia Healthcare Company, Inc.		244,148

Long-Term Debt

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Long-Term Debt

11. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31,
	2022			2021
Credit Facility:
Term Loan A	$	398,438		$	417,031
Revolving Line of Credit		75,000			170,000
5.500% Senior Notes due 2028		450,000			450,000
5.000% Senior Notes due 2029		475,000			475,000
Less: unamortized debt issuance costs, discount and premium		(12,647	)		(14,811	)
		1,385,791			1,497,220
Less: current portion		(21,250	)		(18,594	)
Long-term debt	$	1,364,541		$	1,478,626

New Credit Facility

The Company entered into a credit agreement establishing a new senior credit facility (the “New Credit Facility”) on March 17, 2021. The New Credit Facility provides for a $600.0 million senior secured revolving credit facility (the “Revolving Facility”) and a $425.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Facility, the “Senior Facilities”), each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $20.0 million to be utilized for the issuance of letters of credit and (ii) the availability of a swingline facility under which the Company may borrow up to $20.0 million.

As a part of the closing of the New Credit Facility on March 17, 2021, the Company (i) refinanced and terminated the Company’s prior credit facilities under an amended and restated credit agreement, dated as of December 31, 2012 (the “Prior Credit

Facility”) and (ii) financed the redemption of all of the Company’s outstanding 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”).

The Company had $521.6 million of availability under the Revolving Facility and had standby letters of credit outstanding of $3.4 million related to security for the payment of claims required by its workers’ compensation insurance program at December 31, 2022.

During the year ended December 31, 2022, the Company repaid $95.0 million of the balance outstanding on the Revolving Facility. During the third quarter of 2021, the Company repaid $60.0 million of the initial $160.0 million balance outstanding on the Revolving Facility. During the fourth quarter of 2021, the Company had a draw of $70.0 million on the Revolving Facility related to the CenterPointe acquisition.

The New Credit Facility requires quarterly principal repayments for the Term Loan Facility of $5.3 million for March 31, 2023 to March 31, 2024, $8.0 million for June 30, 2024 to March 31, 2025, $10.6 million for June 30, 2025 to December 31, 2025, with the remaining principal balance of the Term Loan Facility due on the maturity date of March 17, 2026.

The Company has the ability to increase the amount of the Senior Facilities, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the “Incremental Facilities”), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $480.0 million and an amount equal to 100% of the Consolidated EBITDA (as defined in the New Credit Facility) of the Company and its Restricted Subsidiaries (as defined in the New Credit Facility) (as determined for the four fiscal quarter period most recently ended for which financial statements are available), and (ii) additional amounts so long as, after giving effect thereto, the Consolidated Senior Secured Net Leverage Ratio (as defined in the New Credit Facility) does not exceed 3.5 to 1.0.

Subject to certain exceptions, substantially all of the Company’s existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of the Company’s obligations under the New Credit Facility. Borrowings under the Senior Facilities bear interest at a floating rate, which will initially be, at the Company’s option, either (i) adjusted LIBOR plus 1.75% or (ii) an alternative base rate plus 0.75% (in each case, subject to adjustment based on the Company’s consolidated total net leverage ratio). An unused fee initially set at 0.25% per annum (subject to adjustment based on the Company’s consolidated total net leverage ratio) is payable quarterly in arrears based on the actual daily undrawn portion of the commitments in respect of the Revolving Facility.

The New Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the New Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 5.0 to 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The New Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Senior Facilities may be accelerated and/or the lenders’ commitments terminated. At December 31, 2022, the Company was in compliance with such covenants.

Prior Credit Facility

The Company entered into a credit agreement establishing a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an amended and restated credit agreement establishing the Prior Credit Facility, which amended and restated the Senior Secured Credit Facility. The Company amended the Prior Credit Facility from time to time as described in the Company’s prior filings with the SEC.

On April 21, 2020, the Company entered into the Thirteenth Amendment (the “Thirteenth Amendment”) to the Prior Credit Facility. The Thirteenth Amendment amended the Consolidated Leverage Ratio in the prior covenant to increase such leverage ratio for the rest of 2020.

On November 13, 2020, the Company entered into the Fourth Repricing Facilities Amendment (the “Fourth Repricing Facilities Amendment”) to the Prior Credit Facility. The Fourth Repricing Facilities Amendment extended the maturity date of each of the prior revolving line of credit and the Term Loan A Facility of the Prior Credit Facility (“TLA Facility”) from November 30, 2021 to November 30, 2022. The Fourth Repricing Facilities Amendment also (1) replaced the revolving line of credit in an aggregate committed amount of $500.0 million with an aggregate committed amount of approximately $459.0 million and (2) replaced the TLA Facility aggregate outstanding principal amount of approximately $352.4 million with an aggregate principal amount of approximately $318.9 million. The interest rate margin applicable to both facilities remained unchanged from the prior facilities, and the commitment fee applicable to the new revolving line of credit also remained unchanged from the prior revolving line of credit. In connection with the Fourth Repricing Facilities Amendment, the Company recorded a debt extinguishment charge

of $1.0 million, including the write-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statement of operations for the year ended December 31, 2020.

On January 5, 2021, the Company made a voluntary payment of $105.0 million on the Term Loan B Facility Tranche B-4 of the Prior Credit Facility (“Tranche B-4 Facility”). On January 19, 2021, the Company used a portion of the net proceeds from the U.K. Sale to repay the outstanding balances of $311.7 million of the TLA Facility and $767.9 million of the Tranche B-4 Facility. As a part of the closing of the New Credit Facility on March 17, 2021, the Company refinanced and terminated the Prior Credit Facility. At March 31, 2021, in connection with the termination of the Prior Credit Facility, the Company recorded a debt extinguishment charge of $10.9 million, including the write-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statement of operations.

Senior Notes

5.500% Senior Notes due 2028

On June 24, 2020, the Company issued $450.0 million of 5.500% Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021.

5.000% Senior Notes due 2029

On October 14, 2020, the Company issued $475.0 million of 5.000% Senior Notes due 2029 (the “5.000% Senior Notes”). The 5.000% Senior Notes mature on April 15, 2029 and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021. The Company used the net proceeds of the 5.000% Senior Notes to prepay approximately $453.3 million of the outstanding borrowings on the Company’s Term Loan B Facility Tranche B-3 of the Prior Credit Facility (“Tranche B-3 Facility”) and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with the offering. In connection with the 5.000% Senior Notes, the Company recorded a debt extinguishment charge of $2.9 million, including the write-off of discount and deferred financing costs of the Tranche B-3 Facility, which was recorded in debt extinguishment costs in the consolidated statement of operations for the year ended December 31, 2020.

The indentures governing the 5.500% Senior Notes and the 5.000% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the New Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes. On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company had outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes were to mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On March 17, 2021, the Company redeemed the 5.625% Senior Notes.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes were to mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. On March 1, 2021, the Company redeemed the 6.500% Senior Notes.

Redemption of 5.625% Senior Notes and 6.500% Senior Notes

On January 29, 2021, the Company issued conditional notices of full redemption providing for the redemption in full of $650 million of 5.625% Senior Notes and $390 million of 6.500% Senior Notes to the holders of such notes.

On March 1, 2021, the Company satisfied and discharged the indentures governing the 6.500% Senior Notes. In connection with the redemption of the 6.500% Senior Notes, the Company recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.

On March 17, 2021, the Company satisfied and discharged the indentures governing the 5.625% Senior Notes. In connection with the redemption of the 5.625% Senior Notes, the Company recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes were to mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. On June 24, 2020, the Company redeemed the 6.125% Senior Notes.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes were to mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. On June 24, 2020, the Company redeemed the 5.125% Senior Notes.

Redemption of 6.125% Senior Notes and 5.125% Senior Notes

On June 10, 2020, the Company issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and 5.125% Senior Notes on July 10, 2020 (the “Redemption Date”), in each case at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including the Redemption Date (the “Redemption Price”). On June 24, 2020, the Company satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the Company recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the consolidated statement of operations for the year ended December 31, 2020.

Other long-term debt

During the year ended December 31, 2021, the Company repaid other long-term debt of $3.3 million, which is reflected in repayment of long-term debt within financing activities in the consolidated statement of cash flows.

Debt Issuance Costs

Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 2022 were $12.6 million, net of accumulated amortization of $4.6 million. Debt issuance costs at December 31, 2021 were $14.8 million, net of accumulated amortization of $2.4 million. Amortization expense related to debt issuance costs, which is included in interest expense on the consolidated statements of operations, was $2.2 million, $2.8 million and $9.8 million, respectively, for the years ended December 31, 2022, 2021 and 2020.

Other

The aggregate maturities of long-term debt at December 31, 2022 were as follows (in thousands):

2023	$	21,250
2024		29,219
2025		39,844
2026		383,125
2027		—
Thereafter		925,000
Total	$	1,398,438

Financial Information Combined Wholly-Owned Subsidiaries - Summarized Statements of Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 2,610,399	$ 2,314,394	$ 2,089,929
Income from continuing operations before income taxes	374,143	275,760	183,797
Net income	280,033	195,562	(669,199)
Net income attributable to Acadia Healthcare Company, Inc.	273,139	$ 190,635	$ (672,132)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue	2,299,562
Income from continuing operations before income taxes	325,309
Net income	244,148
Net income attributable to Acadia Healthcare Company, Inc.	$ 244,148

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Variable Interest Entities (Tables)

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Consolidated VIEs Assets and Liabilities

The consolidated VIEs assets and liabilities in the Company’s consolidated balance sheets are shown below (in thousands):

	December 31,
	2022		2021
Cash and cash equivalents	$	32,478	$	26,360
Accounts receivable, net		23,789		20,144
Other current assets		2,561		1,304
Total current assets		58,828		47,808
Property and equipment, net		313,358		220,793
Goodwill		39,564		34,945
Intangible assets, net		16,139		10,490
Operating lease right-of-use assets		6,284		6,603
Total assets	$	434,173	$	320,639
Accounts payable	$	4,650	$	3,690
Accrued salaries and benefits		6,866		5,656
Current portion of operating lease liabilities		233		197
Other accrued liabilities		6,179		6,818
Total current liabilities		17,928		16,361
Operating lease liabilities		6,433		6,666
Other liabilities		—		1,083
Total liabilities	$	24,361	$	24,110

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Long-Term Debt (Prior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands									3 Months Ended	12 Months Ended
	Mar. 17, 2021	Jan. 19, 2021	Jan. 05, 2021	Nov. 13, 2020	Apr. 21, 2020	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 29, 2018
Debt Instrument [Line Items]
Date entered into a credit agreement	Mar. 17, 2021
Debt extinguishment costs										$ (24,650)	$ (7,233)
Tranche B-4 Facility [Member]
Debt Instrument [Line Items]
Repayments of credit facility		$ 767,900	$ 105,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount				$ 352,400
Repayments of credit facility		$ 311,700
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into a credit agreement							Dec. 31, 2012	Apr. 01, 2011
Debt instrument maturity date						Nov. 30, 2021
Debt extinguishment costs									$ 10,900
Prior Credit Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Debt instrument maturity date				Nov. 30, 2022
Debt extinguishment costs				$ 1,000
Prior Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Line of credit				459,000								$ 500,000
Prior Credit Facility [Member] \| Term Loan A- Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount				$ 318,900
Thirteenth Amendment [Member]
Debt Instrument [Line Items]
Date entered into a credit agreement					Apr. 21, 2020

Derivatives

12 Months Ended

Dec. 31, 2022

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

18. Derivatives

The Company entered into foreign currency forward contracts during the year ended December 31, 2020 in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In August 2019, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £538.1 million. During the term of the swap agreements, the Company received semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company made semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements resulted in £25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million.

In conjunction with the U.K. Sale in January 2021, the Company settled its cross currency swap liability and outstanding forward contracts as shown in investing activities on the consolidated statement of cash flows.

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 2,610,399	$ 2,314,394	$ 2,089,929
Salaries, wages and benefits (including equity-based compensation expense of $29,635, $37,530 and $22,504, respectively)	1,393,434	1,243,804	1,154,522
Professional fees	158,013	136,739	120,489
Supplies	100,200	90,702	87,241
Rents and leases	45,462	38,519	37,362
Other operating expenses	349,277	301,339	262,272
Income from provider relief fund	(21,451)	(17,900)	(32,819)
Depreciation and amortization	117,769	106,717	95,256
Interest expense, net	69,760	76,993	158,105
Debt extinguishment costs		24,650	7,233
Loss on impairment		24,293	4,751
Transaction-related expenses	23,792	12,778	11,720
Total expenses	2,236,256	2,038,634	1,906,132
Income from continuing operations before income taxes	374,143	275,760	183,797
Provision for income taxes	94,110	67,557	40,606
Income from continuing operations	280,033	208,203	143,191
Loss from discontinued operations, net of taxes		(12,641)	(812,390)
Net income (loss)	280,033	195,562	(669,199)
Net income attributable to noncontrolling interests	(6,894)	(4,927)	(2,933)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 273,139	$ 190,635	$ (672,132)
Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 3.05	$ 2.29	$ 1.60
Loss from discontinued operations		(0.14)	(9.25)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	3.05	2.15	(7.65)
Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	2.98	2.24	1.58
Loss from discontinued operations		(0.14)	(9.17)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 2.98	$ 2.10	$ (7.59)
Weighted-average shares outstanding:
Basic	89,680	88,769	87,875
Diluted	91,555	90,793	88,595

Other Intangible Assets - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($) Facility	Jun. 30, 2021 USD ($) Facility	Dec. 31, 2021 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Number of outpatient \| Facility	1	1
Gross proceeds from sale of business	$ 1,500	$ 4,300	$ 1,511,020
Goodwill write down	700	1,800	$ 2,449
Intangible assets for the disposition	$ 100	$ 200

Summary of Significant Accounting Policies - Additional Information (Detail)				1 Months Ended	3 Months Ended				12 Months Ended
	Oct. 01, 2022 USD ($) Segment	Oct. 01, 2021 USD ($) Segment	Jan. 19, 2021 USD ($)	Aug. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) Facility	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($) Facility Bed	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Significant Accounting Policies [Line Items]
Unfavorable adjustment for professional and general liability claims									$ 5,900,000
Professional and general liability reserve					$ 103,600,000	$ 87,800,000			103,600,000	$ 87,800,000
Professional and general liability reserve current					12,100,000	11,900,000			12,100,000	11,900,000
Professional and general liability reserve noncurrent					91,500,000	75,900,000			91,500,000	75,900,000
Insurance receivable					37,800,000	37,900,000			37,800,000	37,900,000
Insurance receivable - current portion					10,158,000	10,807,000			10,158,000	10,807,000
Insurance receivable noncurrent					27,600,000	27,100,000			27,600,000	27,100,000
Workers compensation insurance claims deductible per accident									500,000
Reserve for workers compensation liability									24,200,000	23,600,000
Accrued salaries and benefits					12,000,000.0	12,000,000.0			12,000,000.0	12,000,000.0
Other long-term liabilities					12,200,000	11,600,000			12,200,000	11,600,000
Depreciation expense									$ 117,800,000	106,700,000	$ 95,300,000
Number of beds, replacement facility \| Bed								260
Non-cash property impairment charge relating to existing facility							$ 1,100,000	$ 23,200,000		24,300,000
Impairment of long-lived assets	$ 0	$ 0			$ 0	$ 0					$ 4,200,000
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other operating expenses	Other operating expenses			Other operating expenses	Other operating expenses					Other operating expenses
Number of reporting units \| Segment	1	1
Number of outpatient \| Facility						1		1
Proceeds from U.K. Sale						$ 1,500,000		$ 4,300,000		1,511,020,000
Goodwill write down						700,000		1,800,000		$ 2,449,000
Intangible assets for the disposition						$ 100,000		$ 200,000
ASU 2021-10 [Member]
Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]					true				true
Change in Accounting Principle, Accounting Standards Update, Adoption Date					Dec. 31, 2022				Dec. 31, 2022
U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Goodwill impairment loss									$ 0
Discontinued Operations [Member] \| U.K. Facilities [Member]
Significant Accounting Policies [Line Items]
Proceeds from U.K. Sale			$ 1,525,000,000
Goodwill impairment loss									356,200,000		$ 356,200,000
Closed Facilities [Member] \| U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Non-cash impairment charge related to indefinite-lived assets											$ 600,000
Maximum [Member]
Significant Accounting Policies [Line Items]
Maximum self insured professional liability limit per claim				$ 10,000,000.0					5,000,000.0
Maximum professional liability aggregate policy limit									$ 75,000,000.0
Maximum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life									50 years
Maximum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life									7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Maximum professional liability retention limit									$ 10,000,000.0
Maximum professional liability aggregate policy limit									$ 70,000,000.0
Minimum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life									10 years
Minimum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life									3 years

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31,
	2022			2021
Credit Facility:
Term Loan A	$	398,438		$	417,031
Revolving Line of Credit		75,000			170,000
5.500% Senior Notes due 2028		450,000			450,000
5.000% Senior Notes due 2029		475,000			475,000
Less: unamortized debt issuance costs, discount and premium		(12,647	)		(14,811	)
		1,385,791			1,497,220
Less: current portion		(21,250	)		(18,594	)
Long-term debt	$	1,364,541		$	1,478,626

Summary of Aggregate Maturities of Long-Term Debt

The aggregate maturities of long-term debt at December 31, 2022 were as follows (in thousands):

2023	$	21,250
2024		29,219
2025		39,844
2026		383,125
2027		—
Thereafter		925,000
Total	$	1,398,438

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

+ Details

Summary of Significant Accounting Policies - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued expenses	$ 26,699	$ 26,791
Accrued interest	17,596	17,418
Cost report payable	13,738	6,487
Insurance liability – current portion	12,128	11,923
Accrued property taxes	9,009	8,375
Government relief funds	8,975	8,550
Contract liabilities	6,653	30,371
Income taxes payable	1,338	5,540
Finance lease liabilities	$ 990	$ 990
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other accrued liabilities	Other accrued liabilities
Other	$ 13,466	$ 10,054
Other accrued liabilities	$ 110,592	$ 126,499